AUTHOR INDEX TO VOLUME 45

In this index in alphabetical order are listed names of authors of all articles and letters. Full citation is given under first author only; reference is made from joint authors. Names which begin with a prefix are entered under the prefix. The month is given as a two letter notation in parentheses.

A

Abrams M see Reiss AL
Adinoff B see Linnoila M; Roy A
Akora PK see Breier A
Allan MJ see Brent DA
Allman CJ see Brent DA
Andorn AC see Nemeroff CB
Andreasen NC, Coryell WH, Rice J, Reich T, Endicott J, Grove WM: Familial rates of affective disorder, report from National Institute of Mental Health Collaborative Study [Andreasen] **44**:461 (My); correction, **45**:776 (Au)
Appelbaum PS see Hoge SK
Asarnow RF see Smalley SL
Asarnow RF, Marder SR, Mintz J, Van Putten T, Zimmerman KE: Differential effect of low and conventional doses of fluphenazine on schizophrenic outpatients with good or poor information-processing abilities, 822 (Se)
Asher DM see Kaufman CA
Askanazi J see Gorman JM
Atkinson JH Jr, Grant I, Kennedy CJ, Richman DD, Spector SA, McCutchan JA: Prevalence of psychiatric disorders among men infected with human immunodeficiency virus, controlled study, 859 (Se)
Auerbach J see Zubenko GS
Averbuck DS see Segal SP
Axelrod S see Halbreich U

B

Babb S see Cohen BM
Babor TF see Robins LN
Baldessarini RJ see Cohen BM; Teicher MH
Baldessarini RJ, Cohen BM, Teicher MH: Significance of neuroleptic dose and plasma level in pharmacological treatment of psychoses, 79 (Ja)
Ballenger JC see Noyes R Jr
Ballenger JC, Burrows GD, DuPont RL Jr, Lesser IM, Noyes R Jr, Pecknold JC, Rifkin A, Swinson RP: Alprazolam in panic disorder and agoraphobia, results from multicenter trial, I. efficacy in short-term treatment, 413 (My)
Balon R, Yeragani VK, Pohl R: Relative hypophosphatemia in patients with panic disorder (letter) 294 (Mr)
Barbaccia M see Roy A
Barber NI see Teicher MH
Barrett JA see Barrett JE
Barrett JE, Barrett JA, Oxman TE, Gerber PD: Prevalence of psychiatric disorders in primary care practice, 1100 (De)
Bartone P see Hogarty GE
Bass C, Gardner WN: Blood gas changes and hypophosphatemia in lactate-induced panic (letter) 95 (Ja)
Bassett AS see Iacono WG
Beardsley RS, Gardocki GJ, Larson DB, Hidalgo J: Prescribing of psychotropic medication by primary care physicians and psychiatrists, 1117 (De)
Bell S see Black DW
Beller SA see Breier A
Berman KF see Goldberg TE; Weinberger DR
Berman KF, Illowsky BP, Weinberger DR: Physiological dysfunction of dorsolateral prefrontal cortex in schizophrenia, IV. further evidence for regional and behavioral specificity, 616 (Jy)
Berman SR see Buysse DJ; Reynolds CF III
Beroza KW see Ravaris CL
Beyer J see Zubenko GS
Biederman J see Rosenbaum JF
Bigelow LB see Ko GN
Bird HR, Canino G, Rubio-Stipec M, Gould MS, Ribera J, Sesman M, Woodbury M, Huertas-Goldman S, Pagan A, Sanchez-Lacay A, Moscoso M: Estimates of prevalence of childhood maladjustment in community survey in Puerto Rico, use of combined measures, 1120 (De)
Bissette G see Nemeroff CB
Bissette G, Nemeroff CB: Somatostatin immunoreactivity in postmortem brain from depressed suicides (letter) 597 (Je)
Black DW see Kuperman S
Black DW, Winokur G, Bell S, Nasrallah A, Hulbert J: Complicated mania, comorbidity and immediate outcome in treatment of mania, 232 (Mr)
Blazer D, Swartz M, Woodbury M, Manton KG, Hughes D, George LK: Depressive symptoms and depressive diagnoses in community population, use of new procedure for analysis of psychiatric classification, 1078 (De)
Blazer DG see Nemeroff CB
Blehar MC, Weissman MM, Gershon ES, Hirschfeld RMA: Family and genetic studies of affective disorders, 289 (Mr)
Bogerts B: Brains of Vogt collection (letter) 774 (Au)
Bonagura N see Mannuzza S
Bondareff W, Mountjoy C, Roth M, Rossor MN, Iversen LL, Reynolds GP: Pathologic heterogeneity of Alzheimer's disease (letter) 963 (Oc)
Bonett D see Mednick SA
Bowden CL see Davis JM; Maas JW
Bowers MB Jr: Plasma monoamine metabolites in psychotic disorders 596 (Je)
Boyd JH see Regier DA
Braff DL, Huey L: Methylphenidate-induced information processing dysfunction in nonschizophrenic patients, 827 (Se)
Breier A see Charney DS; Wolkowitz OM
Breier A, Akora PK, Wolkowitz OM, Pickar D, Paul SM: Metabolic stress produces rapid immunosuppression in humans (letter) **44**:1108 (De); correction, **45**:68 (Ja)
Breier A, Kelsoe JR Jr, Kirwin PD, Beller SA, Wolkowitz OM, Pickar D: Early parental loss and development of adult psychopathology, 987 (No)
Breitner JCS see Mohs RC
Brent D see Costello EJ
Brent DA, Perper JA, Goldstein CE, Kolko DJ, Allan MJ, Allman CJ, Zelenak JP: Risk factors for adolescent suicide, comparison of adolescent suicide victims with suicidal inpatients, 581 (Je)
Breslau N, Prabucki K: Siblings of disabled children, effects of chronic stress in family, **44**:1040 (De); correction, **45**:196 (Fe)
Brinck-Johnsen T see Ravaris CL
Bromet EJ see Penkower L
Brown GM see Szechtman H
Brown RP see Halper JP
Buckholtz NS, George DT, Davies AO, Jimerson DC, Potter WZ: Lymphocyte β-adrenergic receptor modification in bulimia, 479 (My)
Buda M, Tsuang MT, Fleming JA: Causes of death in DSM-III schizophrenics and other psychotics (atypical group), comparison with general population, 283 (Mr)
Buller R see Maier W
Burke J see Robins LN
Burke JD Jr see Regier DA
Burnam MA see Karno M; Koegel P
Burns BJ see Costello EJ
Burns TL see Kuperman S
Burrows GD see Ballenger JC; Lesser IM; Noyes R Jr
Buysse DJ, Reynolds CF III, Kupfer DJ, Houck PR, Hoch CC, Stack JA, Berman SR: Electroencephalographic sleep in depressive pseudodementia, 568 (Je)

C

Cadet JL see Kelsoe JR Jr
Cadoret R see Winokur G
Caillies AL see Popkin MK
Cameron DJ see Thomas RI
Campbell A see Cohen BM
Canino G see Bird HR
Carson S see Halbreich U
Carter M see Hogarty GE
Case WG see Rickels K
Casper R see Davis JM
Cather R see Hogarty GE
Chang I see Georgotas A
Chang SS see Davis JM
Charlton BG, Wright C, Leake A, Ferrier IN, Cheetham SC, Horton RW, Crompton MR, Katona CLE: Somatostatin immunoreactivity in postmortem brain from depressed suicides (letter) 597 (Je)
Charney DS see Heninger GR; Woods SW
Charney DS, Goodman WK, Price LH, Woods SW, Rasmussen SA, Heninger GR: Serotonin function in obsessive-compulsive disorder, comparison of effects of tryptophan and *m*-chlorophenylpiperazine in patients and healthy subjects, 177 (Fe)
Charney DS, Price LH, Breier A: Course of panic attacks and agoraphobia (letter) 502 (My)
Cheetham SC see Charlton BG
Chung H see Rickels K
Clarkin J see Fyer MR
Clarkin JF see Haas GL
Cleghorn JM see Szechtman H
Cloninger CR: Sensation seeking and behavior disorders (letter) 503 (My)
Clozaril Collaborative Study Group see Kane J
Cohen BM see Baldessarini RJ
Cohen BM, Babb S, Campbell A, Baldessarini RJ: Persistence of haloperidol in brain (letter) 879 (Se)
Cohen RM see Newhouse PA; Tariot PN
Cole JO: Where are those new antidepressants we were promised? 193 (Fe)
Colon EA see Popkin MK
Cone EJ see Sherer MA
Contreras SA see Maas JW
Cooley SJ see Hogarty GE
Cooper TB see Georgotas A; Levinson DF
Corenthal C see Zimmerman M
Coryell W see Zimmerman M
Coryell W, Zimmerman M: Heritability of schizophrenia and schizoaffective disorder, family study, 323 (Ap)
Coryell WH see Andreasen NC
Costa E see Roy A
Costello AJ see Costello EJ
Costello EJ, Costello AJ, Edelbrock C, Burns BJ, Dulcan MK, Brent D, Janiszewski S: Psychiatric disorders in pediatric primary care, prevalence and risk factors, 1107 (De)
Cowdry RW see Golden RN
Cowdry RW, Gardner DL: Pharmacotherapy of borderline personality disorder, alprazolam, carbamazepine, trifluoperazine, and tranylcypromine, 111 (Fe)
Coyne L see Spohn HE
Cramer G see Holzman PS
Crits-Christoph P, Luborsky L, Dahl L, Popp C, Mellon J, Mark D: Clinicians can agree in assessing relationship patterns in psychotherapy, core conflictual relationship theme method, 1001 (No)
Crompton MR see Charlton BG
Crowe RR see Paulsen AS
Csanalosi I see Rickels K
Csernansky JG, Riney SJ, Lombrozo L, Overall JE, Hollister LE: Double-blind comparison of alprazolam, diazepam, and placebo for treatment of negative schizophrenic symptoms, 655 (Jy)
Custer R see Roy A

D

Dahl L see Crits-Christoph P
Dauphinais D see Gershon ES
Davidson JRT, Gillier EL, Zisook S, Overall JE: Efficacy study of isocarboxazid and placebo in depression, and its relationship to depressive nosology, 120 (Fe)
Davidson M, Davis KL: Comparison of plasma homovanillic acid concentrations in schizophrenic patients and normal controls, 561 (Je)
Davidson NA: Request for retraction (letter) 685 (Jy)
Davies AO see Buckholtz NS
Davila R, Manero E, Zumarraga M, Andia I, Schweitzer JW, Friedhoff AJ: Plasma homovanillic acid as predictor of response to neuroleptics, 564 (Je)
Davis JM, Koslow SH, Gibbons RD, Maas JW, Bowden CL, Casper R, Hanin I, Javaid JI, Chang SS, Stokes PE: Cerebrospinal fluid and urinary biogenic amines in depressed patients and healthy controls, 705 (Au)
Davis KL see Davidson M; Mohs RC
De Jong J see Roy A
De Vane CL see Golden RN
DeLisi LE see Gershon ES
DeMane N see Haas GL
DePont RL Jr see Ballenger JC
Dew AM see Penkower L
Dhawan M see Posner MI
DiBarry AL see Hogarty GE
Dilsaver SC: Lithium augmentation of antidepressant treatment, partially due to effect on cholinergic mechanism? (letter) 96 (Ja)
Dingman CW II see Gershon ES
Donovan D: Adoptee studies of psychiatric disorders (letter) 875 (Se)
Doran A see Wolkowitz OM
Doran AR see Sack DA
Dulcan MK see Costello EJ
DuPont RL Jr see Lesser IM; Noyes R Jr

E

Early TS see Posner MI
Edelbrock C see Costello EJ
Ehlers CL, Frank E, Kupfer DJ: Social zeitgebers and biological rhythms, unified approach to understanding etiology of depression, 948 (Oc)
Endicott J see Andreasen NC
Environmental/Personal Indicators in the Course of Schizophrenia Research Group see Hogarty GE
Esaiock SM, Norquist GS: Toward a fairer prospective payment system, 1041 (No)

F

Fahs MC see Thomas RI
Fang VS, Jiang H-K, Rose RP, Luchins DJ: Adrenal gland in major depression, enlarged capacity or enhanced sensitivity? (letter) 964 (Oc)
Farde L, Sedvall G, Wiesel F-A, Hall H, Halldin C, Stone-Elander S: Brain dopamine receptors in schizophrenia, PET problems (letter) 599 (Je)
Farde L, Wiesel F-A, Halldin C, Sedvall G: Central D2-dopamine receptor occupancy in schizophrenic patients treated with antipsychotic drugs, 71 (Ja)
Farmer A see Robins LN
Farmer AE, McGuffin P, Gottesman II: Twin studies and genetic models of schizophrenia (letter) 877 (Se)
Farr RK see Koegel P
Feinberg IR, March JD: Cyclic delta peaks during sleep, results of pulsatile endocrine process? (letter) 1140 (De)
Fenton BJ see Gaffney FA
Ferguson DG: Request for retraction (letter) 685 (Jy)
Ferrier IN see Charlton BG
Finkelstein SP see Teicher MH
Firnau G see Szechtman H
Flanagan SD see Holzman PS
Fleming BM see Scott WB
Fleming JA see Buda M; Tsuang MT
Fogarty LA see Rich CL
Fowler RC see Rich CL
Frances AJ see Fyer MR; Kocsis JH
Frank E see Ehlers CL; Kupfer DJ
Frankenburg FR see Hudson JI
Freedman DX:
Is 'lithium cabonate' editorial dictate? (letter) 293 (Mr)
Meaning of full disclosure, collegial trust in science, 689 (Jy)
Request for retraction (letter) 685, 686 (Jy)
SI units now obligatory (editorial note) 691 (Jy)

Freiman MP, Mitchell JB, Rosenbach ML: Simulating policy options for psychiatric care in general hospitals under Medicare's PPS, 1032 (No)
Friedhoff AJ see Davila R
Fyer AJ see Gorman JM
Fyer MR see Gorman JM
Fyer MR, Frances AJ, Sullivan T, Hurt SW, Clarkin J: Comorbidity of borderline personality disorder, 348 (Ap)

G

Gabrielli WF Jr see Martin RL
Gaffney FA, Fenton BJ, Lane LD, Lake CR: Hemodynamic, ventilatory, and biochemical responses of panic patients and normal controls with sodium lactate infusion and spontaneous panic attacks, 53 (Ja)
Gajdusek DC see Kaufman CA
Gardner DL see Cowdry RW
Gardner WN see Base C
Gerdocki GJ see Beardsley RS
Garnett ES see Szechtman H
George DT see Buckholtz NS
George LK see Blazer D; Regier DA
Georgotas A, McCue RE, Cooper TB, Nagachandran N, Chang I: How effective and safe is continuation therapy in elderly depressed patients? factors affecting relapse rate, 929 (Oc)
Gerber PD see Barrett JE
Germanson T see Rosa HE
Gershon ES see Bleher MC
Gershon ES, DeLisi LE, Hamovit J, Nurnberger JI Jr, Maxwell ME, Schreiber J, Dauphinais D, Dingman CW II, Guroff JJ: Controlled family study of chronic psychoses, schizophrenia and schizoaffective disorder, 328 (Ap)
Gershon ES, Hoshe MR: Comment, on deaths of Ernst and Klaus H (letter) 775 (Au)
Gersten M see Rosenbaum JF
Gertsis G see Martin RL
Gibbons RD see Davis JM
Gibbs CJ Jr see Kaufman CA
Gillet EL see Davidson JR
Gladis M see Walsh BT
Glaser FB see Rosa HE
Glassman AH see Walsh BT
Glick ID see Haas GL
Glogowski J see Heibreich U
Goetz DM see Liebowitz MR
Goetz R see Gorman JM
Gold EO see Schuckit MA
Goldberg SC, Schulz SC: Pharmacotherapy for patients with borderline personality disorder (letter) 195 (Fe)
Goldberg TE, Berman KF, Weinberger DR: Prefrontal-type cognitive deficits and chronic psychiatric conditions (letter) 1054 (No)
Golden RN, De Vane CL, Laizure SC, Rudorfer MV, Sherer MA, Potter WZ: Bupropion in depression, II. role of metabolites in clinical outcome, 145 (Fe)
Golden RN, Markey SP, Risby ED, Rudorfer MV, Cowdry RW, Potter WZ: Antidepressants reduce whole-body norepinephrine turnover while enhancing 6-hydroxymelatonin output, 150 (Fe)
Golden RN, Rudorfer MV, Sherer MA, Linnoila M, Potter WZ: Bupropion in depression, I. biochemical effects and clinical response, 139 (Fe)
Goldfinger SM see Segal SP
Golding JM see Karno M
Goldman HH see Taube CA
Goldstein CE see Brent DA
Goldstein MJ see Miklowitz DJ
Good-Ellis M see Haas GL
Goodman WK see Charney DS; Woods SW
Gordon C see Hoge SK
Gorman JM: Blood gas changes and hypophosphatemia in lactate-induced panic (letter) 96 (Ja)
Gorman JM, Fyer MR, Goetz R, Askanazi J, Liebowitz MR, Fyer AJ, Kinney J, Klein DF: Ventilatory physiology of patients with panic disorder, 31 (Ja)
Gottesman II see Farmer AE
Gould MS see Bird HR
Grant I see Atkinson JH Jr
Greenberg DA see Small GW
Greer A see Hoge SK
Gregor M see Kupfer DJ
Griez E, Pois H: Blood gas changes and hypophosphatemia in lactate-induced panic (letter) 96 (Ja)
Grochocinski VJ see Hudson JI; Kupfer DJ
Grove WM see Andreasen NC
Gruenberg AS see Tsuang MT
Gruzelier J, Seymour K, Wilson L, Jolley A, Hirsch S: Impairments on neuropsychologic tests of temporohippocampal and frontohippocampal functions and word fluency in remitting schizophrenia and affective disorders, 623 (Jy)
Guidotti A see Roy A
Gunderson JG: Pharmacotherapy for patients with borderline personality disorder (letter) 196 (Fe)
Guroff JJ see Gershon ES
Guthrie S see Roy A

H

Haas GL, Glick ID, Clarkin JF, Spencer JH, Lewis AB, Peyser J, DeMane N, Good-Ellis M, Harris E, Lestelle V: Inpatient family intervention, randomized clinical trial, II. results at hospital discharge, 217 (Mr)
Hagerman RJ see Reiss AL
Halbreich U, Olympia J, Glogowski J, Carson S, Axelrod S, Yeh C-M: Importance of past psychological trauma and pathophysiological process as determinants of current biologic abnormalities (letter) 293 (Mr)
Hall H see Farde L
Halldin C see Farde L
Halper JP, Brown RP, Sweeney JA, Kocsis JH, Peters A, Mann JJ: Blunted β-adrenergic responsivity of peripheral blood mononuclear cells in endogenous depression, isoproterenol dose- response studies, 241 (Mr)
Hamovit J see Gershon ES
Hanin R see Davis JM
Harris E see Haas GL
Harrison WM see Liebowitz MR
Hayward L see Parker G
Heinssen RK see McGlashan TH
Heinssen RK, McGlashan TH: Predicting hospital discharge status for patients with schizophrenia, schizoaffective disorder, borderline personality disorder, and unipolar affective disorder, 353 (Ap)
Helzer JE see Robins LN
Heninger GR see Charney DS; Woods SW
Heninger GR, Charney DS, Price LH: α_2-adrenergic receptor sensitivity in depression, plasma MHPG, behavioral, and cardiovascular responses to yohimbine, 718 (Au)
Herman JB see Rosenbaum JF
Heston LL: Morbid risk in first-degree relatives of persons with Alzheimer's disease (letter) 97 (Ja)
Hidalgo J see Beardsley RS
Hill JL see Zohar J
Hirsch S see Gruzelier J
Hirschfeld RMA see Bleher MC
Hirshfeld DR see Rosenbaum JF
Hoch CC see Buysse DJ; Reynolds CF III
Hoehe MR see Gershon ES
Hogarty GE, McEvoy JP, Munetz M, DiBarry AL, Bartone P, Cather R, Cooley SJ, Ulrich RF, Carter M, Madonia MJ, Environmental/Personal Indicators in the Course of Schizophrenia Research Group: Dose of fluphenazine, familial expressed emotion, and outcome in schizophrenia, results of 2-year controlled study, 797 (Se)
Hoge SK, Sacha G, Appelbaum PS, Greer A, Gordon C: Limitations on psychiatrists' discretionary civil commitment authority by Stone and dangerousness criteria, 764 (Au)
Hollister LE see Csernansky JG
Holzman PS, Kringlen E, Matthysse S, Flanagan SD, Lipton RB, Cramer G, Levin S, Lange K, Levy DL: Single dominant gene can account for eye tracking dysfunctions and schizophrenia in offspring of discordant twins, 641 (Jy)
Honigfeld G see Kane J
Horton RW see Charlton BG
Houck PR see Buysse DJ; Reynolds CF III
Hudson JI, Lipinski JF, Frankenburg FR, Grochocinski VJ, Kupfer DJ: Electroencephalographic sleep in mania, 267 (Mr)
Huertas-Goldman S see Bird HR
Huey L see Braff DL
Huff FJ see Zubenko GS
Hughes D see Blazer D
Hulbert J see Black DW
Hurt SW see Fyer MR
Huttunen MO see Mednick SA

I

Iacono WG, Bassett AS, Jones BD: Eye tracking dysfunction is associated with partial trisomy of chromosome 5 and schizophrenia (letter) 1140 (De)
Illowsky BP see Berman KF; Weinberger DR
Insel TR see Zohar J
Iversen LL see Bondareff W

J

Jablensky A see Robins LN
Jaeckle R, Krummel SJ, Kathol R, Meller W, Lopez JF: Adrenal gland in major depression, enlarged capacity or enhanced sensitivity? (letter) 965 (Oc)
Jaffe JH see Sherer MA
James SP see Sack DA
Janiszewski S see Costello EJ
Javaid JI see Davis JM
Jernigan TL see Pfefferbaum A
Jiang H-K see Fang VS
Jimerson DC see Buckholtz NS; Ko GN
Johnston DG, Troyer IE, Whitsett SF: Clomipramine treatment of agoraphobic women, 8-week controlled trial, 453 (My)
Johnston P see Parker G
Jolley A see Gruzelier J
Jones BD see Iacono WG

K

Kagan J see Rosenbaum JF
Kane J, Honigfeld G, Singer J, Meltzer H, Clozaril Collaborative Study Group: Clozapine for treatment-resistant schizophrenic, double-blind comparison with chlorpromazine, 789 (Se)
Kaplan RD see Szechtman H
Karno M see Regier DA
Karno M, Golding JM, Sorenson SB, Burnam MA: Epidemiology of obsessive-compulsive disorder in 5 US communities, 1094 (De)
Karoum F see Roy A
Kathol R see Jaeckle R
Katona CLE see Charlton BG
Kaufman CA, Weinberger DR, Stevens JR, Asher DM, Kleinman JE, Sullma MP, Gibbs CJ Jr, Gajdusek DC: Intracerebral inoculation of experimental animals with brain tissue from patients with schizophrenia, failure to observe consistent or specific behavioral and neuropathological effects, 648 (Jy)
Kellams JJ see Small JG
Kelsoe J see Wolkowitz OM
Kelsoe JR Jr see Breier A
Kelsoe JR Jr, Cadet JL, Pickar D, Weinberger DR: Quantitative neuroanatomy in schizophrenia, controlled magnetic resonance imaging study, 533 (Je)
Kendell RE: What is a case? food for thought for epidemiologists, 374 (Ap)
Kendler KS see Tsuang MT
Kendler KS: Familial aggregation of schizophrenia and schizophrenia spectrum disorders, evaluation of conflicting results, 377 (Ap)
Kendler KS, Tsuang MT: Outcome and familial psychopathology in schizophrenia, 338 (Ap)
Kennedy CJ see Atkinson JH Jr
Kerwin RW see Murray RM
Kety SS, Wender PH: Adoptee studies of psychiatric disorders (letter) 875 (Se)
King RA: Neurodevelopmental model of schizophrenia (letter) 1051 (No)
King RJ see Reiss AL
Kinney J see Gorman JM
Kirwin PD see Breier A
Klapper MH see Small JG
Klein DF see Gorman JM; Klein RG; Liebowitz MR
Klein DF:
Cause and treatment of agoraphobia (letter) 389 (Ap)
Drug therapy for agoraphobia (letter) 387 (Ap)
Klein RG see Mannuzza S
Klein RG, Landa B, Mattes JA, Klein DF: Methylphenidate and growth in hyperactive children, controlled withdrawal study, 1127 (De)
Klein RG, Mannuzza S: Hyperactive boys almost grown up, III. methylphenidate effects on ultimate height, 1131 (De)
Kleinman JE see Kaufman CA
Klerman GL: Overview of cross-national collaborative panic study, 407 (My)
Knight DL see Nemeroff CB
Ko GN, Jimerson DC, Wyatt RJ, Bigelow LB: Plasma 3-methoxy-4-hydroxyphenylglycol changes associated with clinical state and schizophrenic subtype, 842 (Se)
Kocsis JH see Halper JP
Kocsis JH, Frances AJ, Voss C, Mann JJ, Mason BJ, Sweeney J: Imipramine treatment for chronic depression, 253 (Mr)
Koegel P, Burnam MA: Alcoholism among homeless adults in inner city of Los Angeles, 1011 (No)
Koegel P, Burnam MA, Farr RK: Prevalence of specific psychiatric disorders among homeless individuals in inner city of Los Angeles, 1085 (De)
Kolko DJ see Brent DA
Konig PH see Mannuzza S
Koslow JM see Davis JM
Kramer M see Regier DA
Kringlen E see Holzman PS
Krishnan KRR see Nemeroff CB
Kritkausky RP see Scott WB
Krummel SJ see Jaeckle R
Kuch K see Pecknold JC
Kumor KM see Sherer MA
Kuperman S, Black DW, Burns TL: Excess mortality among formerly hospitalized child psychiatric patients, 277 (Mr)
Kupfer DJ see Buysse DJ; Ehlers CL; Hudson JI; Reynolds CF III
Kupfer DJ, Frank E, Grochocinski VJ, Gregor M, McEachran AB: Electroencephalographic sleep profiles in recurrent depression, longitudinal investigation, 678 (Jy)

L

Laizure SC see Golden RN
Lake CR see Gaffney FA
Lamparski D see Roy A
Landa B see Klein RG
Lane LD see Gaffney FA
Lange X see Holzman PS
Larson DB see Beardsley RS
Laska EV see Levinson DF
Lawrence JM see Teicher MH
Laske A see Charlton BG
Lee ES see Taube CA
Lelliott P, Marks I: Cause and treatment of agoraphobia (letter) 388 (Ap)
Lentz RD see Popkin MK
Lesser IM see Ballenger JC
Lesser IM, Rubin RT, Pecknold JC, Rifkin A, Swinson RP, Lydiard RB, Burrows GD, Noyes R Jr, DuPont RL Jr: Secondary depression in panic disorder and agoraphobia, I. frequency, severity, and response to treatment, 437 (My)
Lestelle V see Haas GL
Levin S see Holzman PS
Levinson DF: Twin studies and genetic models of schizophrenia (letter) 876 (Se)
Levinson DF, Simpson GM, Singh H, Cooper TB, Laska EV, Midha KK: Neuroleptic plasma level may predict response in patients who meet criterion for improvement (letter) 878 (Se)
Levy DL see Holzman PS
Lewine R: Neurodevelopmental model of schizophrenia (letter) 1051 (No)
Lewis AB see Haas GL
Lewis CP see Pecknold JC
Lieberman HR see Teicher MH
Liebowitz MR see Gorman JM
Liebowitz MR, Quitkin FM, Stewart JW, McGrath PJ, Harrison WM, Markowitz JS, Rabkin JG, Tricamo E, Goetz DM, Klein DF: Antidepressant specificity in atypical depression, 129 (Fe)
Lim KO see Pfefferbaum A
Linnoila M see Golden RN; Roy A; Sack DA
Linnoila M, Oliver J, Adinoff B, Potter WZ: High correlations of norepinephrine, dopamine, and epinephrine and their major metabolite excretion rates, 701

(Au)
Lipinski JF see Hudson JI
Lipton RB see Holzman PS
Locke BZ see Regier DA
Lombrozo L see Caernansky JG
Lopez JF see Jaeckle R
Lorenz V see Roy A
Luborsky L see Crits-Christoph P
Lucas P see Wolkowitz OM
Luchins DJ see Fang VS
Lydiard RB see Lesser IM

M

Maas JW see Davis JM
Maas JW, Contreras SA, Selesh E, Bowden CL: Dopamine metabolism and depression in schizophrenic patients, studies using debrisoquin, 553 (Je)
Machon RA see Mednick SA
Madonia MJ see Hogarty GE
Maier W, Buller R: Course of panic attacks and agoraphobia (letter) 501 (My)
Maier W, Philipp M, Buller R: Value of structured clinical interviews, (letter) 963 (Oc)
Manero E see Davila R
Mann DMA, Yates PO, Marcyniuk B: Pathologic heterogeneity of Alzheimer's disease (letter) 962 (Oc)
Mann JJ see Halper JP; Kocsis JH
Mannuzza S see Klein RG
Mannuzza S, Klein RG, Bonagura N, Konig PH, Shenker R: Hyperactive boys almost grown up, II. status of subjects without mental disorder, 13 (Ja)
Manton KG see Blazer D
March JD see Feinberg IR
Marcyniuk B see Mann DMA
Marder SR see Asarnow RF
Marder SR, Van Putten T: Who should receive clozapine? 865 (Se)
Mark D see Crits-Christoph P
Markey SP see Golden RN
Markowitz JS see Liebowitz MR
Marks I see Lelliott P
Martin RL, Gerteis G, Gabrielli WF Jr: Family-genetic study of dementia of Alzheimer type, 894 (Oc)
Mason BJ see Kocsis JH
Mason-Brothers A see Ritvo ER
Mathew RJ, Wilson WH, Tant SR, Robinson L, Prakash R: Abnormal resting regional cerebral blood flow patterns and their correlates in schizophrenia, 542 (Je)
Mattes JH see Klein RG
Matthysse S see Holzman PS
Maxwell ME see Gershon ES
McCue RE see Georgotas A
McCutchen JA see Atkinson JH Jr
McEachran AB see Kupfer DJ
McEvoy JP see Hogarty GE
McGlashan TH see Heinssen RK
McGlashan TH, Heinssen RK: Hospital discharge status and long-term outcome for patients with schizophrenia, schizoaffective disorder, borderline personality disorder, and unipolar affective disorder, 363 (Ap)
McGrath PJ see Liebowitz MR
McGuffin P see Farmer AE
Mednick SA, Machon RA, Huttunen MO, Bonett D: Adult schizophrenia following prenatal exposure to influenza epidemic, 189 (Fe)
Meller W see Jaeckle R
Mellon J see Crits-Christoph P
Mellow AM see Newhouse PA
Meltzer H see Kane J
Melville ML see Nemeroff CB
Meminger SR see Rosenbaum JF
Menkes JH see Ritvo ER
Meyers JK see Regier DA
Midha KK see Levinson DF
Miklowitz DJ, Goldstein MJ, Nuechterlein KH, Snyder KS, Mintz J: Family factors and course of bipolar affective disorder, 225 (Mr)
Miller MJ see Small JG
Mills MJ: Civil commitment, relationship between perceived dangerousness and mental illness, 770 (Au)
Milstein V see Small JG
Mintz J see Asarnow R; Miklowitz DJ
Mitchell JB see Freiman MP
Mohs RC, Breitner JCS, Silverman JM, Davis KL: Morbid risk in first-degree relatives of persons with Alzheimer's disease (letter) 98 (Ja)
Morihisa JM see Roy BF
Moscoso M see Bird HR
Mountjoy C see Bondareff W
Munetz M see Hogarty GE
Murphy DL see Newhouse PA; Roy BF; Tariot PN; Zohar J
Murphy GE: Suicide and substance abuse, 593 (Je)
Murray RM, Kerwin RW: Neurodevelopmental model of schizophrenia (letter) 1052 (No)

N

Nagachandran N see Georgotas A
Nahmias C see Szechtman H
Nasrallah A see Black DW
Nemeroff CB see Bissette G
Nemeroff CB, Knight DL, Krishnan KRR, Slotkin TA, Bissette G, Melville ML, Blazer DG: Marked reduction in number of platelet—tritiated imipramine binding sites in geriatric depression, 919 (Oc)
Nemeroff CB, Owens MJ, Bissette G, Andorn AC, Stanley M: Reduced corticotropin releasing factor binding sites in frontal cortex of suicide victims, 577 (Je)
Newhouse PA see Tariot PN
Newhouse PA, Sunderland T, Tariot PN, Weingartner H, Thompson K, Mellow AM, Cohen RM, Murphy DL: Effects of acute scopolamine in geriatric depression, 906 (Oc)
Noordsy DL see Ravaris CL
Norquist GS see Essock SM
Noyes R Jr see Ballenger JC; Lesser IM
Noyes R Jr, DuPont RL Jr, Pecknold JC, Rifkin A, Rubin RT, Swinson RP, Ballenger JC, Burrows GD: Alprazolam in agoraphobia with panic attacks and panic disorder, results of multicenter trial, II. patient acceptance, side effects, and safety, 423 (My)
Noyes R see Paulsen AS
Nuechterlein KH see Miklowitz DJ
Nurnberger JI Jr see Gershon ES

O

Oliver J see Linnoila M
Olympia J see Halbreich U
Overall JE see Caernansky JG; Davidson JR
Owen DR see Schiavi RC
Owens MJ see Nemeroff CB
Oxman TE see Barrett JE

P

Pagan A see Bird HR
Papeschi R: Course of panic attacks and agoraphobia (letter) 501 (My)
Pardo PJ see Posner MI
Parker G, Johnston P, Hayward L: Parental 'expressed emotion' as predictor of schizophrenic relapse, 806 (Se)
Paul SM see Breier A; Wolkowitz OM
Paulsen AS, Crowe RR, Noyes R, Pfohl B: Reliability of telephone interview in diagnosing anxiety disorders, 62 (Ja)
Pecknold JC see Ballenger JC; Lesser IM; Noyes R Jr
Pecknold JC, Swinson RP, Kuch K, Lewis CP: Alprazolam in panic disorder and agoraphobia, results of multicenter trial, III. discontinuation effects, 429 (My)
Penkower L, Bromet EJ, Dew AM: Husbands' layoff and wives' mental health, prospective analysis, 994 (No)
Perper JA see Brent DA
Peters A see Halper JP
Peyser J see Haas GL
Pfefferbaum A, Zipursky RB, Lim KO, Zatz LM, Stahl SM, Jernigan TL: Computed tomographic evidence for generalized sulcal and ventricular enlargement in schizophrenia, 633 (Jy)
Pfohl B see Paulsen AS; Zimmerman M
Phillpp M see Maier W
Pickar D see Breier A; Kelsoe JR Jr; Roy A; Wolkowitz OM
Pickens R see Robins JN
Pohl R see Balon R
Poling A: Request for retraction (letter) 686 (Jy)
Pols H see Griez E
Popkin MK, Callies AL, Lentz RD, Colon EA, Sutherland DE: Prevalence of major depression, simple phobia, and other psychiatric disorders in patients with long-standing type I diabetes mellitus, 64 (Ja)
Popp C see Crits-Christoph P
Posner MI, Early TS, Reiman E, Pardo PJ, Dhawan M: Asymmetries in hemispheric control of attention in schizophrenia, 814 (Se)
Potter WZ see Buckholtz NS; Golden RN; Linnoila M
Prabucki K see Breslau N
Prakash R see Mathew RJ
Price LH see Charney DS; Heninger GR
Price TR see Starkstein SE

Q

Quitkin FM see Liebowitz MR

R

Rabkin JG see Liebowitz MR
Rae DS see Regier DA
Rasmussen SA see Charney DS
Ravaris CL, Satsis MJ, Beroza KW, Noordsy DL, Brinck-Johnsen T: Effect of ketoconazole on hypophysectomized, hypercortisolemic, psychotically depressed woman (letter) 966 (Oc)
Regier DA see Robins LN
Regier DA, Boyd JH, Burke JD Jr, Rae DS, Myers JK, Kramer M, Robins LN, George LK, Karno M, Locke BZ: One-month prevalence of mental disorders in United States, based on 5 epidemiologic catchment area sites, 977 (No)
Reich T see Andreasen NC
Reiman E see Posner MI
Reiss AL, Hagerman RJ, Vinogradov S, Abrams M, King RJ: Psychiatric disability in female carriers of fragile X chromosome, 25 (Ja)
Rey JM see Stewart GW
Reynolds CF III see Buysse DJ
Reynolds CF III, Kupfer DJ, Houck PR, Hoch CC, Stack JA, Berman SR, Zimmer B: Reliable discrimination of elderly depressed and demented patients by electroencephalographic sleep data, 258 (Mr)
Reynolds CF see Bondareff W
Reznick JS see Rosenbaum JF
Ribera J see Bird HR
Rice J see Andreasen NC
Rich CL, Fowler RC, Fogarty LA, Young D: San Diego Suicide Study, III. relationships between diagnosis and stressors, 589 (Je)
Richman DD see Atkinson JH Jr
Rickels K, Schweizer E, Csanalosi I, Case WG, Chung H: Long-term treatment of anxiety and risk withdrawal, prospective comparison of clorazepate and buspirone, 444 (My)
Rifkin A see Ballenger JC; Lesser IM; Noyes R Jr
Riney SJ see Caernansky JG
Risby ED see Golden RN
Ritvo ER, Mason-Brothers A, Menkes JH, Sparkes RS: Association of autism, retinoblastoma, and reduced esterase D activity (letter) 600 (Je)
Robins LN see Regier DA
Robins LN, Wing J, Wittchen HU, Helzer JE, Babor TF, Burke J, Farmer A, Jablenski A, Pickens R, Regier DA, Sartorius N, Towle LH: Composite international diagnostic interview, epidemiologic instrument suitable for use in conjunction with different diagnostic systems and in different cultures, 1069 (De)
Robinson L see Mathew RJ
Robinson RG see Starkstein SE
Roehrich L see Roy A
Roose SP see Walsh BT
Rose JW see Roy BF
Rose RP see Fang VS
Rosenbach ML see Freiman MP
Rosenbaum JF, Biederman J, Gersten M, Hirshfeld DR, Meminger SR, Herman JB, Kagan J, Reznick JS, Snidman N: Behavioral inhibition in children of parents with panic disorder and agoraphobia, controlled study, 463 (My)
Ross HE, Glaser FB, Germanson T: Prevalence of psychiatric disorders in patients with alcohol and other drug problems, 1023 (No)
Roseor MN see Bondareff W
Roth M see Bondareff W
Roy A, Adinoff B, Roehrich L, Lamparski D, Custer R, Lorenz V, Barbaccia M, Guidotti A, Costa E, Linnoila M: Pathological gambling, psychobiological study, 369 (Ap)
Roy A, Guthrie S, Karoum F, Pickar D, Linnoila M: High intercorrelations among urinary outputs of norepinephrine and its major metabolites, replication in depressed patients and controls, 158 (Fe)
Roy A, Pickar D, De Jong J, Karoum F, Linnoila M: Norepinephrine and its metabolites in cerebrospinal fluid, plasma, and urine, relationship to hypothalamic-pituitary-adrenal axis function in depression, 849 (Se)
Roy BF, Rose JW, Sunderland T, Morihisa JM, Murphy DL: Antisomatostatin IgG in major depressive disorder, preliminary study with implications for autoimmune mechanism of depression, 924 (Oc)
Rubin RT see Lesser IM; Noyes R Jr
Rubio-Stipec M see Bird HR
Rudorfer MV see Golden RN
Rutter M: Epidemiological approaches to developmental psychopathology, 486 (My)

S

Sachs G see Hoge SK
Sack DA, James SP, Doran AR, Sherer MA, Linnoila M, Wehr TA: Diurnal variation in plasma homovanillic acid level persists but variation in 3-methoxy-4-hydroxyphenylglycol level is abolished under constant conditions, 162 (Fe)
Sanchez-Lacay A see Bird HR
Sartorius N see Robins LN
Satsis MJ see Ravaris CL
Schiavi RC, Theilgaard A, Owen DR, White D: Sex chromosome anomalies, hormones, and sexuality, 19 (Ja)
Schnurr P see Valliant GE
Schou M: Is 'lithium carbonate' editorial dictate? (letter) 293 (Mr)
Schreiber J see Gershon ES
Schuckit MA, Gold EO: Simultaneous evaluation of multiple markers of ethanol/placebo challenges in sons of alcoholics and controls, 211 (Mr)
Schulz SC see Goldberg SC
Schweitzer JW see Davila R
Schweizer E see Rickels K
Scott WB, Fleming BM, Kritkausky RP: Drug therapy for agoraphobia (letter) 387 (Ap)
Sedvall G see Farde L
Seeman P: Brain dopamine receptors in schizophrenia: PET problems (letter) 598 (Je)
Segal SP, Watson MA, Goldfinger SM, Averbuck DS: Civil commitment in psychiatric emergency room, I. assessment of dangerousness by emergency room clinicians, 748; II. mental disorder indicators and 3 dangerousness criteria, 753; III. disposition as function of mental disorder and dangerousness indicators, 759 (Au)
Selesh E see Maas JW
Seaman M see Bird HR
Seymour K see Gruzelier J
Sharpley PH see Small JG
Shenker R see Mannuzza S
Sherer MA see Golden RN; Sack DA
Sherer MA, Kumor KM, Cone EJ, Jaffe JH: Suspiciousness induced by 4-hour intravenous infusions of cocaine, preliminary findings, 673 (Jy)
Silverman JM see Mohs RC
Simpson GM see Levinson DF
Singer J see Kane J
Singh H see Levinson DF
Siris SG: Implications of normal brain development for pathogenesis of schizophrenia (letter) 1055 (No)
Slotkin TA see Nemeroff CB
Small GW, Greenberg DA: Biologic markers, genetics, and Alzheimer's disease, 945 (Oc)
Small IF see Small JG
Small JG, Klapper MH, Kellams JJ, Miller MJ, Milstein V, Sharpley PH, Small IF: Electroconvulsive treatment compared with lithium in management of manic states, 727 (Au)
Smalley SL, Asarnow RF, Spence MA: Autism and genetics, decade of research, 953 (Oc)
Snidman N see Rosenbaum JF
Snyder KS see Miklowitz DJ

Sorenson SB see Karno M
Sparkes RS see Ritvo ER
Spector SA see Atkinson JH Jr
Spence MA see Smalley SL
Spencer JH see Hess GL
Spitzer RL, Williams JBW: Having a dream, research strategy for *DSM-IV*, 871 (Se)
Spohn HE, Coyne L, Spray J: Effect of neuroleptics and tardive dyskinesia on smooth-pursuit eye movement in chronic schizophrenics, 833 (Se)
Spray J see Spohn HE
Stack JA see Buysse DJ; Reynolds CF III
Stahl SM see Pfefferbaum A
Stangl D see Zimmerman M
Stanley M see Nemeroff CB
Starkstein SE, Robinson RG, Price TR: Comparison of patients with and without poststroke major depression matched for size and location of lesion, 247 (Mr)
Steiner F see Walsh BT
Stevens JR see Kaufman CA
Stewart GW, Rey JM: Partial solution to base rate problem κ statistic (letter) 504 (My)
Stewart JW see Liebowitz MR; Walsh BT
Stokes PE see Davis JM
Stone-Elander S see Farde L
Sullena MP see Kaufman CA
Sullivan T see Fyer MR
Sunderland T see Newhouse PA; Roy BF; Tariot PN
Sutherland DE see Popkin MK
Swartz M see Blazer D
Sweeney JA see Halper JP; Kocsis JH
Swinson RP see Ballenger JC; Lesser IM; Noyes R Jr; Pecknold JC
Szechtman H, Nahmias C, Garnett ES, Firnau G, Brown GM, Kaplan RD, Cleghorn JM: Effect of neuroleptics on altered cerebral glucose metabolism in schizophrenia, 523 (Je)

T

Tant SR see Mathew RJ
Tariot PN see Newhouse PA
Tariot PN, Cohen RM, Welkowitz JA, Sunderland T, Newhouse PA, Murphy DL, Weingartner H: Multiple-dose arecoline infusions in Alzheimer's disease, 901 (Oc)
Taube CA, Goldman HH, Lee ES: Use of specialty psychiatric settings in constructing DRGs, 1037 (No)
Teicher MH see Baldessarini RJ
Teicher MH, Lawrence JM, Barber NI, Finklestein SP, Lieberman HR, Baldessarini RJ: Increased activity and phase delay in circadian motility rhythms in geriatric depression, preliminary observations, 913 (Oc)
Tennant C: Parental loss in childhood, its effect in adult life, 1045 (No)
Teply I see Zubenko GS
Thallgaard A see Schlavi RC
Thomas RI, Cameron OJ, Faha MC: Prospective study of delirium and prolonged hospital stay, exploratory study, 987 (Oc)
Thompson K see Newhouse PA
Towle LH see Robins LN
Tricamo E see Liebowitz MR
Troyer IE see Johnston DG
Tsuang MT see Buda M; Kendler KS
Tsuang MT, Fleming JA, Kendler KS, Gruenberg AS: Selection of controls for family studies, biases and implications, 1006 (No)

U

Ulrich RF see Hogarty GE

V

Vaillant GE, Schnurr P: What is case? 45-year study of psychiatric impairment within college sample selected for mental health, 313 (Ap)
Van Putten T see Asarnow RF; Marder SR
Vinogradov S see Reiss AL
Voss C see Kocsis JH

W

Walsh BT, Gladis M, Roose SP, Stewart JW, Stetner F, Glassman AH: Phenelzine vs placebo in 55 patients with bulimia, 471 (My)
Watson MA see Segal SP
Wehr TA see Sack DA
Weinberger DR see Berman KF; Goldberg TE; Kaufman CA; Kolsoe JR Jr
Weinberger DR: Neurodevelopmental model of schizophrenia (letter) 1053 (No)
Weinberger DR, Berman KF, Illowsky BP: Physiological dysfunction of dorsolateral prefrontal cortex in schizophrenia, III. new cohort and evidence for monoaminergic mechanism, 609 (Jy)
Weingartner H see Newhouse PA; Tariot PN
Weissman MM see Blehar MC
Welkowitz JA see Tariot PN
Wender PH see Kety SS
White D see Schlavi RC
Whitsett SF see Johnston DG
Wiesel F-A see Farde L
Williams JBW see Spitzer RL
Williams JBW: Structured interview guide for Hamilton depression rating scale, 742 (Au)
Wilson L see Gruzelier J
Wilson WH see Mathew RJ
Wing J see Robins LN
Winokur G see Black DW
Winokur G, Zimmerman M, Cadoret R: 'Cause the Bible tells me so, 683 (Jy)
Wittchen HU see Robins LN
Wolkowitz OM see Breier A
Wolkowitz OM, Breier A, Doran A, Kelsoe J, Lucas P, Paul SM, Pickar D: Alprazolam augmentation of antipsychotic effects of fluphenazine in schizophrenic patients, preliminary results, 664 (Jy)
Wong M-L: Prefrontal-type cognitive deficits and chronic psychiatric conditions (letter) 1054 (No)
Woodbury M see Bird HR; Blazer D
Woods SW see Charney DS
Woods SW, Charney DS, Goodman WK, Heninger GR: Carbon dioxide-induced anxiety, behavioral, physiologic, and biochemical effects of carbon dioxide in patients with panic disorders and healthy subjects, 43 (Ja)
Wright C see Charlton BG
Wyatt RJ see Ko GN

Y

Yates PO see Mann DMA
Yeh C-M see Halbreich U
Yeragani VK see Balon R
Young D see Rich CL

Z

Zatz LM see Pfefferbaum A
Zelenak JP see Brent DA
Zimmer S see Reynolds CF III
Zimmerman KE see Asarnow RF
Zimmerman M see Coryell W; Winokur G
Zimmerman M: Why are we rushing to publish *DSM-IV*? 1135 (De)
Zimmerman M, Coryell W: Validity of self-report questionnaire for diagnosing major depressive disorder, 738 (Au)
Zimmerman M, Coryell W, Pfohl B, Stangl D: Reliability of family history method for psychiatric diagnoses, 820 (Ap)
Zimmerman M, Pfohl B, Coryell W, Stangl D, Corenthal C: Diagnosing personality disorder in depressed patients, comparison of patient and informant interviews, 733 (Au)
Zipursky RB see Pfefferbaum A
Zisook S see Davidson JR
Zohar J, Insel TR, Zohar-Kadouch RC, Hill JL, Murphy DL: Serotonergic responsivity in obsessive-compulsive disorder, effects of chronic clomipramine treatment, 167 (Fe)
Zohar-Kadouch RC see Zohar J
Zubenko GS, Huff FJ, Beyer J, Auerbach J, Teply I: Familial risk of dementia associated with biologic subtype of Alzheimer's disease, 889 (Oc)
Zuckerman M: Sensation seeking and behavior disorders (letter) 502 (My)
Zumarraga M see Davila R

SUBJECT INDEX TO VOLUME 45

The following index is an alphabetical list of significant subjects presented in this volume. The month is given as a two letter notation in parentheses.

Abnormalities
importance of past psychological trauma and pathophysiological process as determinants of current biologic abnormalities (letter) [Halbreich] 293 (Mr)
Acquired Immunodeficiency Syndrome
prevalence of psychiatric disorders among men infected with human immunodeficiency virus, controlled study [Atkinson] 859 (Se)
Adenosine Monophosphate
blunted β-adrenergic responsivity of peripheral blood mononuclear cells in endogenous depression, isoproterenol dose-response studies [Halper] 241 (Mr)
Adjustment Disorders
estimates of prevalence of childhood maladjustment in community survey in Puerto Rico, use of combined measures [Bird] 1120 (De)
Administration Schedule, Drug see Drug Administration Schedule
Adoption
adoptee studies of psychiatric disorders (letter) [Donovan] (reply) [Kety] 875 (Se)
Adrenal Cortex Hormones
adrenal gland in major depression, enlarged capacity or enhanced sensitivity? (letter) [Fang] 964, (reply) [Jaeckle] 965 (Oc)
Adrenal Gland Hyperfunction
adrenal gland in major depression, enlarged capacity or enhanced sensitivity? (letter) [Fang] 964, (reply) [Jaeckle] 965 (Oc)
effect of ketoconazole on hypophysectomized, hypercortisolemic, psychotically depressed woman (letter) [Ravaris] 966 (Oc)
Adrenergic Alpha Receptors see Receptors, Adrenergic, Alpha
Adrenergic Beta Receptor Blockaders
blunted β-adrenergic responsivity of peripheral blood mononuclear cells in endogenous depression, isoproterenol dose-response studies [Halper] 241 (Mr)
Adrenocorticotropic Hormone
early parental loss and development of psychopathology [Breier] 987 (No)
Affective Disorders
antidepressants reduce whole-body norepinephrine turnover while enhancing 6-hydroxymelatonin output [Golden] 150 (Fe)
antisomatostatin IgG in major depressive disorder, preliminary study with implications for autoimmune mechanism of depression [Roy] 924 (Oc)
comorbidity of borderline personality disorder [Fyer] 348 (Ap)
electroencephalographic sleep in mania [Hudson] 267 (Mr)
familial rates of affective disorder, report from National Institute of Mental Health Collaborative Study [Andreasen] 44:461 (My); correction, 45:776 (Au)
family and genetic studies of affective disorders [Blehar] 289 (Mr)
family factors and course of bipolar affective disorder [Mikkelsen] 225 (Mr)
heritability of schizophrenia and schizoaffective disorder, Iowa study [Corgiat] 323 (Ap)
high intercorrelations among urinary outputs of norepinephrine and its major metabolites, replication in depressed patients and controls [Roy] 158 (Fe)
hospital discharge status and long-term outcome for patients with schizophrenia, schizoaffective disorder, borderline personality disorder, and unipolar affective disorder [McGlashan] 363 (Ap)
husbands' layoff and wives' mental health, prospective analysis [Penkower] 994 (No)
impairments on neuropsychologic tests of temporohippocampal and frontohippocampal functions and word fluency in remitting schizophrenia and affective disorders [Gruzelier] 623 (Jy)
inpatient family intervention, randomized clinical trial, II. results at hospital discharge [Haas] 217 (Mr)
one-month prevalence of mental disorders in United States, based on 5 epidemiologic catchment area sites [Regier] 977 (No)
outcome and familial psychopathology in schizophrenia [Kendler] 338 (Ap)
predicting hospital discharge status for patients with schizophrenia, schizoaffective disorder, borderline personality disorder, and unipolar affective disorder [Heinssen] 353 (Ap)
psychiatric disability in female carriers of fragile X chromosome [Reiss] 25 (Ja)
reliability of telephone interview in diagnosing anxiety disorders [Paulsen] 62 (Ja)
risk factors for adolescent suicide, comparison of adolescent suicide victims with suicidal inpatients [Brent] 581 (Je)
San Diego Suicide Study, III. relationships between diagnoses and stressors [Rich] 589 (Je)
secondary depression in panic disorder and agoraphobia, I. frequency, severity, and response to treatment [Lesser] 437 (My)
selection of controls for family studies, biases and implications [Tsuang] 1006 (No)
twin studies and genetic models of schizophrenia (letter) [Levinson] 876, (reply) [Farmer] 877 (Se)
Affective Psychosis, Bipolar see Bipolar Disorders
Age Factors
epidemiologic approaches to developmental psychopathology [Rutter] 486 (My)
morbid risk in first-degree relatives of persons with Alzheimer's disease (letter) [Heston] 97, (reply) [Moha] 98 (Ja)
one-month prevalence of mental disorders in United States, based on 5 epidemiologic catchment area sites [Regier] 977 (No)
pathologic heterogeneity of Alzheimer's disease (letter) [Mann] 962, (reply) [Bondareff] 963 (Oc)
prevalence of specific psychiatric disorders among homeless individuals in inner city of Los Angeles [Koegel] 1085 (De)
Aged
how effective and safe is continuation therapy in elderly depressed patients, factors affecting relapse rate [Georgotas] 929 (Oc)
reliable discrimination of elderly depressed and demented patients by electroencephalographic sleep data [Reynolds] 258 (Mr)
Aggression
hyperactive boys almost grown up, II. status of subjects without mental disorder [Mannuzza] 13 (Ja)
Agonistic Behavior see Aggression
Agoraphobia see Phobic Disorders

Agranulocytosis
clozapine for treatment-resistant schizophrenic, double-blind comparison with chlorpromazine [Kane] 789 (Se)
who should receive clozapine? [Marder] 865 (Se)
AIDS-Related Complex
prevalence of psychiatric disorders among men infected with human immunodeficiency virus, controlled study [Atkinson] 859 (Se)
Alcohol Drinking
San Diego Suicide Study, III. relationships between diagnoses and stressors [Rich] 589 (Je)
Alcohol, Ethyl
simultaneous evaluation of multiple markers of ethanol/placebo challenges in sons of alcoholics and controls [Schuckit] 211 (Mr)
Alcoholism
alcoholism among homeless adults in inner city of Los Angeles [Koegel] 1011 (No)
controlled family study of chronic psychoses, schizophrenia and schizoaffective disorder [Gershon] 328 (Ap)
high correlations of norepinephrine, dopamine, and epinephrine and their major metabolite excretion rates [Linnoila] 701 (Au)
outcome and familial psychopathology in schizophrenia [Kendler] 338 (Ap)
prevalence of psychiatric disorders among men infected with human immunodeficiency virus, controlled study [Atkinson] 859 (Se)
prevalence of psychiatric disorders in patients with alcohol and other drug problems [Ross] 1023 (No)
simultaneous evaluation of multiple markers of ethanol/placebo challenges in sons of alcoholics and controls [Schuckit] 211 (Mr)
suicide and substance abuse [Murphy] 593 (Je)
Alprazolam
alprazolam augmentation of antipsychotic effects of fluphenazine in schizophrenic patients, preliminary results [Wolkowitz] 664 (Jy)
alprazolam in agoraphobia with panic attacks and panic disorder, results of multicenter trial, I. efficacy in short-term treatment [Bellenger] 413; II. patient acceptance, side effects, and safety [Noyes] 423; III. discontinuation effects [Pecknold] 429 (My)
double-blind comparison of alprazolam, diazepam, and placebo for treatment of negative schizophrenic symptoms [Csernansky] 655 (Jy)
pharmacotherapy of borderline personality disorder, alprazolam, carbamazepine, trifluoperazine, and tranylcypromine [Cowdry] 111 (Fe)
secondary depression in panic disorder and agoraphobia, I. frequency, severity, and response to treatment [Lesser] 437 (My)
where are those new antidepressants we were promised? [Cole] 193 (Fe)
Alzheimer's Disease
biologic markers, genetics, and Alzheimer's disease [Small] 945 (Oc)
familial risk of dementia associated with biologic subtype of Alzheimer's disease [Zubenko] 889 (Oc)
family genetic study of dementia of Alzheimer type [Martin] 894 (Oc)
morbid risk in first-degree relatives of persons with Alzheimer's disease (letter) [Heston] 97, (reply) [Mohs] 98 (Ja)
multiple-dose arecoline infusions in Alzheimer's disease [Tariot] 901 (Oc)
pathologic heterogeneity of Alzheimer's disease (letter) [Mann] 962, (reply) [Bondareff] 963 (Oc)
somatostatin immunoreactivity in postmortem brain from depressed suicides (letter) [Charlton] (reply) [Bissette] 597 (Je)
Aminoscridines
multiple-dose arecoline infusions in Alzheimer's disease [Tariot] 901 (Oc)
Aminobutyric Acids
long-term treatment of anxiety and risk of withdrawal, prospective comparison of clorazepate and buspirone [Rickels] 444 (My)
Amitriptyline
lithium augmentation of antidepressant treatment, partially due to effect on cholinergic mechanism? (letter) [Dilsaver] 96 (Ja)
Amoxapine see Dibenzazepines
Amphetamine
suspiciousness induced by 4-hour intravenous infusions of cocaine, preliminary findings [Sherer] 673 (Jy)
Amphetamines
prevalence of psychiatric disorders in patients with alcohol and other drug problem [Ross] 1023 (No)
Animals, Laboratory
intracerebral inoculation of experimental animals with brain tissue from patients with schizophrenia, failure to observe consistent or specific behavioral and neuropathological effects [Kaufmann] 648 (Jy)
Anticholinergic Agents see Parasympatholytics
Antidepressants, Tricyclic see Antidepressive Agents, Tricyclic
Antidepressive Agents
antidepressant specificity in atypical depression [Liebowitz] 129 (Fe)
antidepressants reduce whole-body norepinephrine turnover while enhancing 6-hydroxymelatonin output [Golden] 150 (Fe)
bupropion in depression, I. biochemical effects and clinical response, 139; II. role of metabolites in clinical outcome [Golden] 145 (Fe)
how effective and safe is continuation therapy in elderly depressed patients, factors affecting relapse rate [Georgotas] 929 (Oc)
imipramine treatment for chronic depression [Kocsis] 253 (Mr)
implications of normal brain development for pathogenesis of schizophrenia (letter) [Siris] 1055 (No)
prescribing of psychotropic medication by primary care physicians and psychiatrists [Beardsley] 1117 (De)
Antidepressive Agents, Tricyclic
alprazolam in agoraphobia with panic attacks and panic disorder, results of multicenter trial, II. patient acceptance, side effects, and safety [Noyes] 423 (My)
clomipramine treatment of agoraphobic women, 8-week controlled trial [Johnston] 453 (My)
lithium augmentation of antidepressant treatment, partially due to effect on cholinergic mechanism? (letter) [Dilsaver] 96 (Ja)
where are those new antidepressants we were promised? [Cole] 193 (Fe)
Antipsychotic Agents see Tranquilizing Agents, Major
Antisocial Personality Disorder
one-month prevalence of mental disorders in United States, based on 5 epidemiologic catchment area sites [Regier] 977 (No)
prevalence of psychiatric disorders in patients with alcohol and other drug problems [Ross] 1023 (No)
risk factors for adolescent suicide, comparison of adolescent suicide victims with suicidal inpatients [Brent] 581 (Je)
Anxiety Disorders
α_2-adrenergic receptor sensitivity in depression, plasma MHPG, behavioral, and cardiovascular responses to yohimbine [Heninger] 718 (Au)
alprazolam in panic disorder and agoraphobia, results from multicenter trial, I. efficacy in short-term treatment [Ballenger] 413; III. discontinuation effects [Pecknold] 429 (My)
behavioral inhibition in children of parents with panic disorder and agoraphobia, controlled study [Rosenbaum] 463 (My)
carbon dioxide-induced anxiety, behavioral, physiologic, and biochemical effects of carbon dioxide in patients with panic disorders and healthy subjects [Woods] 43 (Ja)
course of panic attacks and agoraphobia (letters) [Maier, Papeschi] 501, (reply) [Charney] 502 (My)
depressive symptoms and depressive diagnosis in community population, use of new procedure for analysis of psychiatric classification [Blazer] 1078 (De)
estimates of prevalence of childhood maladjustment in community survey in Puerto Rico, use of combined measures [Bird] 1120 (De)
long-term treatment of anxiety and risk of withdrawal, prospective comparison of clorazepate and buspirone [Rickels] 444 (My)
one-month prevalence of mental disorders in United States, based on 5 epidemiologic catchment area sites [Regier] 977 (No)
outcome and familial psychopathology in schizophrenia [Kendler] 338 (Ap)
overview of cross-national collaborative panic study [Klerman] 407 (My)
prevalence of psychiatric disorders among men infected with human immunodeficiency virus, controlled study [Atkinson] 859 (Se)
prevalence of psychiatric disorders in patients with alcohol and other drug problems [Ross] 1023 (No)
prevalence of psychiatric disorders in primary care practice [Barrett] 1100 (De)
secondary depression in panic disorder and agoraphobia, I. frequency, severity, and response to treatment [Lesser] 437 (My)
sensation seeking and behavior disorders (letter) [Zuckerman] 502, (reply) [Cloninger] 503 (My)
ventilatory physiology of patients with panic disorder [Gorman] 31 (Ja)
Anxiety Neuroses see Anxiety Disorders
Anxiety States, Neurotic see Anxiety Disorders
ARCHIVES OF GENERAL PSYCHIATRY
is 'lithium carbonate' editorial dictate? (letter) [Schou] (reply) [Freedman] 293 (Mr)
reviewers for 1988, 1067 (De)
Arecholin see Arecoline
Arecoline
multiple-dose arecoline infusions in Alzheimer's disease [Tariot] 901 (Oc)
Ataractics see Tranquilizing Agents
Ataxia
simultaneous evaluation of multiple markers of ethanol/placebo challenges in sons of alcoholics and controls [Schuckit] 211 (Mr)
Attention
asymmetries in hemispheric control of attention in schizophrenia [Posner] 814 (Se)
Attention Deficit Disorder with Hyperactivity
hyperactive boys almost grown up, II. status of subjects without mental disorder [Mannuzza] 13 (Ja)
hyperactive boys almost grown up, III. methylphenidate effects on ultimate height [Klein] 1131 (De)
Autism
association of autism, retinoblastoma, and reduced esterase D activity (letter) [Ritvo] 600 (Je)
Autism, Infantile
autism and genetics, decade of research [Smalley] 953 (Oc)
Autoimmune Diseases
antisomatostatin IgG in major depressive disorder, preliminary study with implications for autoimmune mechanism of depression [Roy] 924 (Oc)

B

Bayes Theorem see Probability
Benzodiazepine Tranquilizers
long-term treatment of anxiety and risk of withdrawal, prospective comparison of clorazepate and buspirone [Rickels] 444 (My)
Benzodiazepines
alprazolam in agoraphobia with panic attacks and panic disorder, results of multicenter trial, I. efficacy in short-term treatment [Bellenger] 413; II. patient acceptance, side effects, and safety [Noyes] 423; III. discontinuation effects [Pecknold] 429 (My)
overview of cross-national collaborative panic study [Klerman] 407 (My)
Benztropine see Tropanes
Beta-Endorphin
antisomatostatin IgG in major depressive disorder, preliminary study with implications for autoimmune mechanism of depression [Roy] 924 (Oc)
Binding Sites
marked reduction in number of platelet-tritiated imipramine binding sites in geriatric depression [Nemeroff] 919 (Oc)
Biochemistry
carbon dioxide-induced anxiety, behavioral, physiologic, and biochemical effects of carbon dioxide in patients with panic disorders and healthy subjects [Woods] 43 (Ja)
hemodynamic, ventilatory, and biochemical responses of panic patients and normal controls with sodium lactate infusion and spontaneous panic attacks [Gaffney] 53 (Ja)
Biology
social zeitgebers and biological rhythms, unified approach to understanding etiology of depression [Ehlers] 948 (Oc)
Biomedical Research see Research
Bipolar Disorder
controlled family study of chronic psychoses, schizophrenia and schizoaffective disorder [Gershon] 328 (Ap)
electroconvulsive treatment compared with lithium in management of manic states [Small] 727 (Au)
family and genetic studies of affective disorders [Blehar] 289 (Mr)
family factors and course of bipolar affective disorder [Miklowitz] 225 (Mr)
increased activity and phase delay in circadian motility rhythms in geriatric depression, preliminary observations [Teicher] 913 (Oc)
outcome and familial psychopathology in schizophrenia [Kendler] 338 (Ap)
risk factors for adolescent suicide, comparison of adolescent suicide victims with suicidal inpatients [Brent] 581 (Je)
significance of neuroleptic dose and plasma level in pharmacological treatment of psychoses [Baldessarini] 79 (Ja)
Blood Cell Count
relative hypophosphatemia in patients with panic disorder (letter) [Balon] 294 (Mr)
Blood Flow Velocity
abnormal resting regional cerebral blood flow patterns and their correlates in schizophrenia [Mathew] 542 (Je)
physiological dysfunction of dorsolateral prefrontal cortex in schizophrenia, III. new cohort and evidence for monoaminergic mechanism [Weinberger] 609; IV. further evidence for regional and behavioral specificity [Berman] 616 (Jy)
prefrontal-type cognitive deficits and chronic psychiatric conditions (letter) [Wong] (reply) [Goldberg] 1054 (No)
Blood Gas Analysis
blood gas changes and hypophosphatemia in lactate-induced panic (letters) [Bass, Gries] 95, 96, (reply) [Gorman] 96 (Ja)
Blood Platelets
familial risk of dementia associated with biologic subtype of Alzheimer's disease [Zubenko] 889 (Oc)
marked reduction in number of platelet-tritiated imipramine binding sites in geriatric depression [Nemeroff] 919 (Oc)
Blood Pressure
ventilatory physiology of patients with panic disorder [Gorman] 31 (Ja)
Body Height
hyperactive boys almost grown up, III. methylphenidate effects on ultimate height [Klein] 1131 (De)
methylphenidate and growth in hyperactive children, controlled withdrawal study [Klein] 1127 (De)
Body Weight
methylphenidate and growth in hyperactive children, controlled withdrawal study [Klein] 1127 (De)
Borderline Personality Disorder see Personality Disorders
Brain
abnormal resting regional cerebral blood flow patterns and their correlates in schizophrenia [Mathew] 542 (Je)
cyclic delta peaks during sleep, result of pulsatile endocrine process? (letter) [Feinberg] 1140 (De)
intracerebral inoculation of experimental animals with brain tissue from patients with schizophrenia, failure to observe consistent or specific behavioral and neuropathological effects [Kaufmann] 648 (Jy)
methylphenidate-induced information processing dysfunction in nonschizophrenic patients [Braff] 827 (Se)
persistence of haloperidol in brain (letter) [Cohen] 879 (Se)
Brain Diseases
implications of normal brain development for pathogenesis of schizophrenia (letter) [Siris] 1055 (No)
neurodevelopmental model of schizophrenia (letters) [King, Lewine, Murray] 1051, 1052, (reply) [Weinberger] 1053 (No)
quantitative neuroanatomy in schizophrenia, controlled magnetic resonance imaging study [Kelsoe] 533 (Je)
reduced corticotropin releasing factor binding sites in frontal cortex of suicides [Nemeroff] 577 (Je)
Brain Mapping
quantitative neuroanatomy in schizophrenia, controlled magnetic resonance imaging study [Kelsoe] 533 (Je)
Bulimia
lymphocyte β-adrenergic receptor modification in bulimia [Buckholtz] 479 (My)
phenelzine vs placebo in 50 patients with bulimia [Walsh] 471 (My)

Bupropion
bupropion in depression, I. biochemical effects and clinical response, 139; II. role of metabolites in clinical outcome [Golden] 145 (Fe)
where are those new antidepressants we were promised? [Cole] 193 (Fe)
Buspirone
long-term treatment of anxiety and risk of withdrawal, prospective comparison of clorazepate and buspirone [Rickels] 444 (My)
Butylscopolammonium Bromide see Scopolamine Derivatives

C

Capgras Syndrome see Psychotic Disorders
Carbamazepine
pharmacotherapy of borderline personality disorder, alprazolam, carbamazepine, trifluoperazine, and tranylcypromine [Cowdry] 111 (Fe)
Carbon Dioxide
carbon dioxide-induced anxiety, behavioral, physiologic, and biochemical effects of carbon dioxide in patients with panic disorders and healthy subjects [Woods] 43 (Ja)
Cardiovascular Diseases
causes of death in *DSM-III* schizophrenics and other psychotics (atypical group), comparison with general population [Buda] 283 (Mr)
Catecholamines
blunted β-adrenergic responsivity of peripheral blood mononuclear cells in endogenous depression, isoproterenol dose-response studies [Halper] 241 (Mr)
cerebrospinal fluid and urinary biogenic amines in depressed patients and healthy controls [Davis] 705 (Au)
high intercorrelations among urinary outputs of norepinephrine and its major metabolites, replication in depressed patients and controls [Roy] 158 (Fe)
Catechols
alprazolam augmentation of antipsychotic effects of fluphenazine in schizophrenic patients, preliminary results [Wolkowitz] 664 (Jy)
antidepressants reduce whole-body norepinephrine turnover while enhancing 6-hydroxymelatonin output [Golden] 150 (Fe)
dopamine metabolism and disposition in schizophrenic patients, studies using debrisoquin [Maas] 553 (Je)
high intercorrelations among urinary outputs of norepinephrine and its major metabolites, replication in depressed patients and controls [Roy] 158 (Fe)
norepinephrine and its metabolites in cerebrospinal fluid, plasma, and urine, relationship to hypothalamic-pituitary-adrenal axis function in depression [Roy] 849 (Se)
pathological gambling, psychobiological study [Roy] 369 (Ap)
sensation seeking and behavior disorders (letter) [Zuckerman] 502, (reply) [Cloninger] 503 (My)
Cebidae
intracerebral inoculation of experimental animals with brain tissue from patients with schizophrenia, failure to observe consistent or specific behavioral and neuropathological effects [Kaufmann] 648 (Jy)
Central Nervous System
adult schizophrenia following prenatal exposure to influenza epidemic [Mednick] 189 (Fe)
differential effect of low and conventional doses of fluphenazine on schizophrenic outpatients with good or poor information-processing abilities [Asarnow] 822 (Se)
familial risk of dementia associated with biologic subtype of Alzheimer's disease [Zubenko] 889 (Oc)
marked reduction in number of platelet-tritiated imipramine binding sites in geriatric depression [Nemeroff] 919 (Oc)
Cercopithecidae
intracerebral inoculation of experimental animals with brain tissue from patients with schizophrenia, failure to observe consistent or specific behavioral and neuropathological effects [Kaufmann] 648 (Jy)
Cerebral Cortex
neurodevelopmental model of schizophrenia (letters) [King, Lewine, Murray] 1051, 1052, (reply) [Weinberger] 1053 (No)
physiological dysfunction of dorsolateral prefrontal cortex in schizophrenia, III. new cohort and evidence for monoaminergic mechanism [Weinberger] 609;, IV. further evidence for regional and behavioral specificity [Berman] 616 (Jy)
Cerebrospinal Fluid
antisomatostatin IgG in major depressive disorder, preliminary study with implications for autoimmune mechanisms of depression [Roy] 924 (Oc)
bupropion in depression, I. biochemical effects and clinical response, 139; II. role of metabolites in clinical outcome [Golden] 145 (Fe)
cerebrospinal fluid and urinary biogenic amines in depressed patients and healthy controls [Davis] 705 (Au)
computed tomographic evidence for generalized sulcal and ventricular enlargement in schizophrenia [Pfefferbaum] 633 (Jy)
diurnal variation in plasma homovanillic acid level persists but variation in 3-methoxy-4-hydroxyphenylglycol level is abolished under constant conditions [Sack] 162 (Fe)
dopamine metabolism and disposition in schizophrenic patients, studies using debrisoquin [Maas] 553 (Je)
norepinephrine and its metabolites in cerebrospinal fluid, plasma, and urine, relationship to hypothalamic-pituitary-adrenal axis function in depression [Roy] 849 (Se)
pathological gambling, psychobiological study [Roy] 369 (Ap)
physiological dysfunction of dorsolateral prefrontal cortex in schizophrenia, III. new cohort and evidence for monoaminergic mechanism [Weinberger] 609; IV. further evidence for regional and behavioral specificity [Berman] 616 (Jy)
plasma monoamine metabolites in psychotic disorders [Bowers] 595 (Je)
plasma 3-methoxy-4-hydroxyphenylglycol changes associated with clinical state and schizophrenic subtype [Ko] 842 (Se)
sensation seeking and behavior disorders (letter) [Zuckerman] 502, (reply) [Cloninger] 503 (My)
serotonin function in obsessive-compulsive disorder, comparison of effects of tryptophan and *m*-chlorophenylpiperazine in patients and healthy subjects [Charney] 177 (Fe)
somatostatin immunoreactivity in postmortem brain from depressed suicides (letter) [Charlton] (reply) [Bissette] 597 (Je)
Cerebrovascular Disorders
comparison of patients with and without poststroke major depression matched for size and location of lesion [Starkstein] 247 (Mr)
Child, Hospitalized
excess mortality among formerly hospitalized child psychiatric patients [Kuperman] 277 (Mr)
Chlorimipramine see Clomipramine
Chlorpromazine
clozapine for treatment-resistant schizophrenic, double-blind comparison with chlorpromazine [Kane] 789 (Se)
who should receive clozapine? [Marder] 865 (Se)
Cholinergic-Blocking Agents see Parasympatholytics
Cholinesterases
multiple-dose arecoline infusions in Alzheimer's disease [Tariot] 901 (Oc)
Chromatography
antisomatostatin IgG in major depressive disorder, preliminary study with implications for autoimmune mechanism of depression [Roy] 924 (Oc)
Chromatography, Gas
comparison of plasma homovanillic acid concentrations in schizophrenic patients and normal controls [Davidson] 561 (Je)
Chromosome Abnormalities
autism and genetics, decade of research [Smalley] 953 (Oc)
eye tracking dysfunction is associated with partial trisomy of chromosome 5 and schizophrenia (letter) [Iacono] 1140 (De)
morbid risk in first-degree relatives of persons with Alzheimer's disease (letter) [Heston] 97, (reply) [Mohs] 98 (Ja)
sex chromosome anomalies, hormones, and sexuality [Schiavi] 19 (Ja)
single dominant gene can account for eye tracking dysfunctions and schizophrenia in offspring of discordant twins [Holzman] 641 (Jy)
Chromosome 21 see Chromosomes, Human Pair 21
Chromosomes, Human Pair 21
family-genetic study of dementia of Alzheimer type [Martin] 894 (Oc)
Circadian Rhythm
increased activity and phase delay in circadian motility rhythms in geriatric depression, preliminary observations [Teicher] 913 (Oc)
Classification
causes of death in *DSM-III* schizophrenics and other psychotics (atypical group), comparison with general population [Buda] 283 (Mr)
'cause the Bible tells me so [Winokur] 683 (Jy)
clinicians can agree in assessing relationship patterns in psychotherapy, core conflictual relationship theme method [Crits-Christoph] 1001 (No)
depressive symptoms and depressive diagnosis in community population, use of new procedure for analysis of psychiatric classification [Blazer] 1078 (De)
having a dream, research strategy for *DSM-IV* [Spitzer] 871 (Se)
importance of past psychological trauma and pathophysiological process as determinants of current biologic abnormalities (letter) [Halbreich] 293 (Mr)
prevalence of psychiatric disorders in primary care practice [Barrett] 1100 (De)
sensation seeking and behavior disorders (letter) [Zuckerman] 502, (reply) [Cloninger] 503 (My)
value of structured clinical interviews (letter) [Maier] 963 (Oc)
why are we rushing to publish *DSM-IV*? [Zimmerman] 1135 (De)
Clinical Trials
alprazolam in panic disorder and agoraphobia, results from multicenter trial, I. efficacy in short-term treatment [Ballenger] 413 (My)
clomipramine treatment of agoraphobic women, 8-week controlled trial [Johnston] 453 (My)
clozapine for treatment-resistant schizophrenic, double-blind comparison with chlorpromazine [Kane] 789 (Se)
inpatient family intervention, randomized clinical trial, II. results at hospital discharge [Haas] 217 (Mr)
who should receive clozapine? [Marder] 865 (Se)
Clomipramine
clomipramine treatment of agoraphobic women, 8-week controlled trial [Johnston] 453 (My)
serotonergic responsivity in obsessive-compulsive disorder, effects of chronic clomipramine treatment [Zohar] 167 (Fe)
Clozapine see Dibenzazepines
Cocaine
suspiciousness induced by 4-hour intravenous infusions of cocaine, preliminary findings [Sherer] 673 (Jy)
Cognition Disorders
asymmetries in hemispheric control of attention in schizophrenia [Posner] 814 (Se)
effects of acute scopolamine in geriatric depression [Newhouse] 906 (Oc)
electroencephalographic sleep in depressive pseudodementia [Buysse] 568 (Je)
one-month prevalence of mental disorders in United States, based on 5 epidemiologic catchment area sites [Regier] 977 (No)
prefrontal-type cognitive deficits and chronic psychiatric conditions (letter) [Wong] (reply) [Goldberg] 1054 (No)
Commitment of Mentally Ill
civil commitment in psychiatric emergency room, I. assessment of dangerousness by emergency room clinicians [Segal] 748; II. mental disorder indicators and 3 dangerousness criteria [Segal] 753; III. disposition as function of mental disorder and dangerousness indicators [Segal] 759 (Au)
civil commitment, relationship between perceived dangerousness and mental illness [Mills] 770 (Au)
limitations on psychiatrists' discretionary civil commitment authority by Stone and dangerousness criteria [Hoge] 764 (Au)
Controlled Clinical Trials see Clinical Trials
Convergence, Ocular see Eye Movements
Convulsive Therapy, Electric see Electroconvulsive Therapy
Corpus Striatum
effect of neuroleptics on altered cerebral glucose metabolism in schizophrenia [Szechtman] 523 (Je)
Corticotropin
adrenal gland in major depression, enlarged capacity or enhanced sensitivity? (letter) [Fang] 964, (reply) [Jaeckle] 965 (Oc)
Corticotropin Releasing Hormone
reduced corticotropin releasing factor binding sites in frontal cortex of suicides [Nemeroff] 577 (Je)
Cortisol see Hydrocortisone
Costs and Cost Analysis
prospective study of delirium and prolonged hospital stay, exploratory study [Thomas] 937 (Oc)
simulating policy options for psychiatric care in general hospitals under Medicare's PPS [Freiman] 1032 (No)
Cosyntropin
adrenal gland in major depression, enlarged capacity or enhanced sensitivity? (letter) [Fang] 964, (reply) [Jaeckle] 965 (Oc)
Crime
meaning of full disclosure, collegial trust in science [Freedman] 689 (Jy)
request for retraction (letters) [Ferguson, Davidson, Poling] 685, 686, (editorial comment) [Freedman] 686 (Jy)
Cross Sectional Studies see Epidemiologic Methods

D

Dangerous Behavior see Violence
Data Banks see Information Systems
Data Bases see Information Systems
Data Collection
cause and treatment of agoraphobia (letter) [Lelliott] 388, (reply) [Klein] 389 (Ap)
civil commitment, relationship between perceived dangerousness and mental illness [Mills] 770 (Au)
diagnosing personality disorder in depressed patients, comparison of patient and informant interviews [Zimmerman] 733 (Au)
drug therapy for agoraphobia (letter) [Scott] (reply) [Klein] 387 (Ap)
epidemiologic approaches to developmental psychopathology [Rutter] 486 (My)
estimates of prevalence of childhood maladjustment in community survey in Puerto Rico, use of combined measures [Bird] 1120 (De)
familial rates of affective disorder, report from National Institute of Mental Health Collaborative Study [Andreasen] 44:461 (My); correction, 45:776 (Au)
prevalence of psychiatric disorders in primary care practice [Barrett] 1100 (De)
quantitative neuroanatomy in schizophrenia, controlled magnetic resonance imaging study [Kelsoe] 523 (Je)
reliability of telephone interview in diagnosing anxiety disorders [Paulsen] 62 (Ja)
selection of controls for family studies, biases and implications [Tsuang] 1006 (No)
why are we rushing to publish *DSM-IV*? [Zimmerman] 1135 (De)
Data Systems see Information Systems
Debrisoquin see Isoquinolines
Decision Making
civil commitment in psychiatric emergency room, I. assessment of dangerousness by emergency room clinicians [Segal] 748; II. mental disorder indicators and 3 dangerousness criteria [Segal] 753;, III. disposition as function of mental disorder and dangerousness indicators [Segal] 759 (Au)
civil commitment, relationship between perceived dangerousness and mental illness [Mills] 770 (Au)
limitations on psychiatrists' discretionary civil commitment authority by Stone and dangerousness criteria [Hoge] 764 (Au)
simulating policy options for psychiatric care in general hospitals under Medicare's PPS [Freiman] 1032 (No)
toward a fairer prospective payment system [Essock] 1041 (No)
who should receive clozapine? [Marder] 865 (Se)
Delirium
prospective study of delirium and prolonged hospital stay, exploratory study [Thomas] 937 (Oc)
Dementia
electroencephalographic sleep in depressive pseudodementia [Buysse] 568 (Je)
familial risk of dementia associated with biologic subtype of Alzheimer's disease [Zubenko] 889 (Oc)
family-genetic study of dementia of Alzheimer type [Martin] 894 (Oc)
marked reduction in number of platelet-tritiated imipramine binding sites in geriatric depression [Nemeroff] 919 (Oc)
prefrontal-type cognitive deficits and chronic psychiatric

conditions (letter) [Wong] (reply) [Goldberg] 1054 (No)
reliable discrimination of elderly depressed and demented patients by electroencephalographic sleep data [Reynolds] 258 (Mr)
Depression, Endogenous see Depressive Disorder
Depression, Neurotic see Depressive Disorder
Depression, Unipolar see Depressive Disorder
Depressive Disorder
adoptee studies of psychiatric disorders (letter) [Donovan] (reply) [Kety] 875 (Se)
adrenal gland in major depression, enlarged capacity or enhanced sensitivity? (letter) [Fang] 964, (reply) [Jaeckle] 965 (Oc)
α_2-adrenergic receptor sensitivity in depression, plasma MHPG, behavioral, and cardiovascular responses to yohimbine [Heninger] 718 (Au)
antidepressant specificity in atypical depression [Liebowitz] 129 (Fe)
antisomatostatin IgG in major depressive disorder, preliminary study with implications for autoimmune mechanism of depression [Roy] 924 (Oc)
behavioral inhibition in children of parents with panic disorder and agoraphobia, controlled study [Rosenbaum] 463 (My)
blunted β-adrenergic responsivity of peripheral blood mononuclear cells in endogenous depression, isoproterenol dose-response studies [Halper] 241 (Mr)
bupropion in depression, I. biochemical effects and clinical response, 139; II. role of metabolites in clinical outcome [Golden] 145 (Fe)
cerebrospinal fluid and urinary biogenic amines in depressed patients and healthy controls [Davis] 705 (Au)
clomipramine treatment of agoraphobic women, 8-week controlled trial [Johnston] 453 (My)
comparison of patients with and without poststroke major depression matched for size and location of lesion [Starkstein] 247 (Mr)
complicated mania, comorbidity and immediate outcome in treatment of mania [Black] 232 (Mr)
controlled family study of chronic psychoses, schizophrenia and schizoaffective disorder [Gershon] 328 (Ap)
depressive symptoms and depressive diagnosis in community population, use of new procedure for analysis of psychiatric classification [Blazer] 1078 (De)
diagnosing personality disorder in depressed patients, comparison of patient and informant interviews [Zimmerman] 733 (Au)
effect of ketoconazole on hypophysectomized, hypercortisolemic, psychotically depressed woman (letter) [Ravaris] 966 (Oc)
effects of acute scopolamine in geriatric depression [Newhouse] 906 (Oc)
efficacy study of isocarboxazid and placebo in depression, and its relationship to depressive nosology [Davidson] 120 (Fe)
electroconvulsive treatment compared with lithium in management of manic states [Small] 727 (Au)
electroencephalographic sleep in depressive pseudodementia [Buysse] 568 (Je)
electroencephalographic sleep profiles in recurrent depression, longitudinal investigation [Kupfer] 678 (Jy)
familial rates of affective disorder, report from National Institute of Mental Health Collaborative Study [Andreasen] **44**:461 (My); correction, **45**:776 (Au)
family and genetic studies of affective disorders [Blehar] 289 (Mr)
heritability of schizophrenia and schizoaffective disorder, family study [Coryell] 323 (Ap)
high correlations of norepinephrine, dopamine, and epinephrine and their major metabolite excretion rates [Linnoila] 701 (Au)
high intercorrelations among urinary outputs of norepinephrine and its major metabolites, replication in depressed patients and controls [Roy] 158 (Fe)
how effective and safe is continuation therapy in elderly depressed patients, factors affecting relapse rate [Georgotas] 929 (Oc)
imipramine treatment for chronic depression [Kocsis] 253 (Mr)
increased activity and phase delay in circadian motility rhythms in geriatric depression, preliminary observations [Teicher] 913 (Oc)
marked reduction in number of platelet-tritiated imipramine binding sites in geriatric depression [Nemeroff] 919 (Oc)
metabolic stress produces rapid immunosuppression in humans (letter) [Breier] **44**:1108 (De); correction **45**:68 (Ja)
norepinephrine and its metabolites in cerebrospinal fluid, plasma, and urine, relationship to hypothalamic-pituitary-adrenal axis function in depression [Roy] 849 (Se)
outcome and familial psychopathology in schizophrenia [Kendler] 338 (Ap)
overview of cross-national collaborative panic study [Klerman] 407 (My)
parental loss in childhood, its effect in adult life [Tennant] 1045 (No)
prevalence of major depression, simple phobia, and other psychiatric disorders in patients with long-standing type I diabetes mellitus [Popkin] 64 (Ja)
prevalence of psychiatric disorders among men infected with human immunodeficiency virus, controlled study [Atkinson] 859 (Se)
prevalence of psychiatric disorders in patients with alcohol and other drug problems [Ross] 1023 (No)
prevalence of psychiatric disorders in primary care practice [Barrett] 1100 (De)
reduced corticotropin releasing factor binding sites in frontal cortex of suicides [Nemeroff] 577 (Je)
reliability of family history method for psychiatric diagnoses [Zimmerman] 320 (Ap)
reliability of telephone interview in diagnosing anxiety disorders [Paulsen] 62 (Ja)
reliable discrimination of elderly depressed and demented patients by electroencephalographic sleep data [Reynolds] 258 (Mr)
secondary depression in panic disorder and agoraphobia, I. frequency, severity, and response to treatment [Lesser] 437 (My)
siblings of disabled children, effects of chronic stress in family [Breslau] **44**:1040 (De); correction, **45**:196 (Fe)
single dominant gene can account for eye tracking dysfunctions and schizophrenia in offspring of discordant twins [Holzman] 641 (Jy)
social zeitgebers and biological rhythms, unified approach to understanding etiology of depression [Ehlers] 948 (Oc)
somatostatin immunoreactivity in postmortem brain from depressed suicides (letter) [Charlton] (reply) [Bissette] 597 (Je)
structured interview guide for Hamilton depression rating scale [Williams] 742 (Au)
validity of self-report questionnaire for diagnosing major depressive disorder [Zimmerman] 738 (Au)
where are those new antidepressants we were promised? [Cole] 193 (Fe)
why are we rushing to publish *DSM-IV*? [Zimmerman] 1135 (De)
Depressive Syndrome see Depressive Disorder
Dexamethasone
adrenal gland in major depression, enlarged capacity or enhanced sensitivity? (letter) [Fang] 964, (reply) [Jaeckle] 965 (Oc)
importance of past psychological trauma and pathophysiological process as determinants of current biologic abnormalities (letter) [Halbreich] 293 (Mr)
increased activity and phase delay in circadian motility rhythms in geriatric depression, preliminary observations [Teicher] 913 (Oc)
Dextroamphetamine
methylphenidate and growth in hyperactive children, controlled withdrawal study [Klein] 1127 (De)
Diabetes Mellitus, Insulin-Dependent
prevalence of major depression, simple phobia, and other psychiatric disorders in patients with long-standing type diabetes mellitus [Popkin] 64 (Ja)
Diagnosis
biologic markers, genetics, and Alzheimer's disease [Small] 945 (Oc)
'cause the Bible tells me so [Winokur] 683 (Jy)
civil commitment in psychiatric emergency room, I. assessment of dangerousness by emergency room clinicians [Segal] 748; II. mental disorder indicators and 3 dangerousness criteria [Segal] 753;, III. disposition as function of mental disorder and dangerousness indicators [Segal] 759 (Au)
civil commitment, relationship between perceived dangerousness and mental illness [Mills] 770 (Au)
comorbidity of borderline personality disorder [Fyer] 348 (Ap)
composite international diagnostic interview, epidemiologic instrument suitable for use in conjunction with different diagnostic systems and in different cultures [Robins] 1069 (De)
controlled family study of chronic psychoses, schizophrenia and schizoaffective disorder [Gershon] 328 (Ap)
depressive symptoms and depressive diagnosis in community population, use of new procedure for analysis of psychiatric classification [Blazer] 1078 (De)
diagnosing personality disorder in depressed patients, comparison of patient and informant interviews [Zimmerman] 733 (Au)
epidemiology of obsessive-compulsive disorder in 5 US communities [Karno] 1094 (De)
estimates of prevalence of childhood maladjustment in community survey in Puerto Rico, use of combined measures [Bird] 1120 (De)
having a dream, research strategy for *DSM-IV* [Spitzer] 871 (Se)
hospital discharge status and long-term outcome for patients with schizophrenia, schizoaffective disorder, borderline personality disorder, and unipolar affective disorder [McGlashan] 363 (Ap)
hyperactive boys almost grown up, II. status of subjects without mental disorder [Mannuzza] 13 (Ja)
limitations on psychiatrists' discretionary civil commitment authority by Stone and dangerousness criteria [Hoge] 764 (Au)
parental 'expressed emotion' as predictor of schizophrenic relapse [Parker] 806 (Se)
partial solution to base rate problem of κ statistic (letter) [Stewart] 504 (My)
predicting hospital discharge status for patients with schizophrenia, schizoaffective disorder, borderline personality disorder, and unipolar affective disorder [Heinssen] 353 (Ap)
psychiatric disorders in pediatric primary care, prevalence and risk factors [Costello] 1107 (De)
reliability of family history method for psychiatric diagnoses [Zimmerman] 320 (Ap)
reliability of telephone interview in diagnosing anxiety disorders [Paulsen] 62 (Ja)
San Diego Suicide Study, III. relationships between diagnoses and stressors [Rich] 589 (Je)
structured interview guide for Hamilton depression rating scale [Williams] 742 (Au)
validity of self-report questionnaire for diagnosing major depressive disorder [Zimmerman] 738 (Au)
value of structured clinical interviews (letter) [Maier] 963 (Oc)
what is a case? food for thought for epidemiologists [Kendell] 374 (Ap)
what is a case? 45-year study of psychiatric impairment within college sample selected for mental health [Vaillant] 313 (Ap)
why are we rushing to publish *DSM-IV*? [Zimmerman] 1135 (De)
Diagnostic Errors
reliability of family history method for psychiatric diagnoses [Zimmerman] 320 (Ap)
Diagnostic Related Groups
prospective study of delirium and prolonged hospital stay, exploratory study [Thomas] 937 (Oc)
simulating policy options for psychiatric care in general hospitals under Medicare's PPS [Freiman] 1032 (No)
toward a fairer prospective payment system [Essock] 1041 (No)
use of specialty psychiatric settings in constructing DRGs [Taube] 1037 (No)
Diazepam
double-blind comparison of alprazolam, diazepam, and placebo for treatment of negative schizophrenic symptoms [Csernansky] 655 (Jy)
Dibenzazepines
central D2-dopamine receptor occupancy in schizophrenic patients treated with antipsychotic drugs [Farde] 71 (Ja)
clozapine for treatment-resistant schizophrenic, double-blind comparison with chlorpromazine [Kane] 789 (Se)
who should receive clozapine? [Marder] 865 (Se)
Divorce
parental loss in childhood, its effect in adult life [Tennant] 1045 (No)
DNA
autism and genetics, decade of research [Smalley] 953 (Oc)
DNA, Recombinant
family and genetic studies of affective disorders [Blehar] 289 (Mr)
Dopamine
bupropion in depression, I. biochemical effects and clinical response [Golden] 139 (Fe)
comparison of plasma homovanillic acid concentrations in schizophrenic patients and normal controls [Davidson] 561 (Je)
dopamine metabolism and disposition in schizophrenic patients, studies using debrisoquin [Maas] 553 (Je)
high correlations of norepinephrine, dopamine, and epinephrine and their major metabolite excretion rates [Linnoila] 701 (Au)
implications of normal brain development for pathogenesis of schizophrenia (letter) [Siris] 1055 (No)
methylphenidate-induced information processing dysfunction in nonschizophrenic patients [Braff] 827 (Se)
plasma homovanillic acid as predictor of response to neuroleptics [Davila] 564 (Je)
Dopamine Beta-Hydroxylase
autism and genetics, decade of research [Smalley] 953 (Oc)
sensation seeking and behavior disorders (letter) [Zuckerman] 502, (reply) [Cloninger] 503 (My)
Dopamine Receptors see Receptors, Dopamine
Dose-Response Relationship, Drug
significance of neuroleptic dose and plasma level in pharmacological treatment of psychoses [Baldessarini] 79 (Ja)
Down's Syndrome
family-genetic study of dementia of Alzheimer type [Martin] 894 (Oc)
Drug Administration Schedule
alprazolam in panic disorder and agoraphobia, results of multicenter trial, III. discontinuation effects [Pecknold] 429 (My)
dose of fluphenazine, familial expressed emotion, and outcome in schizophrenia, results of 2-year controlled study [Hogarty] 797 (Se)
overview of cross-national collaborative panic study [Klerman] 407 (My)
Drug Evaluation
where are those new antidepressants we were promised? [Cole] 193 (Fe)
Drug Evaluation, FDA Phase III see Clinical Trials
Drug Evaluation, FDA Phase IV see Clinical Trials
Drug Therapy
cause and treatment of agoraphobia (letter) [Lelliott] 388, (reply) [Klein] 389 (Ap)
pharmacotherapy for patients with borderline personality disorder (letter) [Goldberg] 195, (reply) [Gunderson] 196 (Fe)
pharmacotherapy of borderline personality disorder, alprazolam, carbamazepine, trifluoperazine, and tranylcypromine [Cowdry] 111 (Fe)
Drug Withdrawal Symptoms see Substance Withdrawal Syndrome
Dyskinesia, Drug-Induced
differential effect of low and conventional doses of fluphenazine on schizophrenic outpatients with good or poor information-processing abilities [Asarnow] 822 (Se)
effect of neuroleptics and tardive dyskinesia on smooth-pursuit eye movement in chronic schizophrenics [Spohn] 833 (Se)
Dyskinesia, Tardive see Dyskinesia, Drug-Induced
Dysthymic Disorder see Depressive Disorder

E

ECT (Psychotherapy) see Electroconvulsive Therapy
EDITORIAL COMMENT
SI units now obligatory [Freedman] 691 (Jy)
Efficiency
clinicians can agree in assessing relationship patterns in psychotherapy, core conflictual relationship theme method [Crits-Christoph] 1001 (No)
reliability of family history method for psychiatric diagnoses [Zimmerman] 320 (Ap)
Electrocardiography
hemodynamic, ventilatory, and biochemical responses of panic patients and normal controls with sodium lactate infusion and spontaneous panic attacks [Gaffney] 53 (Ja)

Electroconvulsive Therapy
complicated mania, comorbidity and immediate outcome in treatment of mania [Black] 232 (Mr)
electroconvulsive treatment compared with lithium in management of manic state: [Small] 727 (Au)
Electroencephalography
cyclic delta peaks during sleep, result of pulsatile endocrine process? (letter) [Feinberg] 1140 (De)
electroencephalographic sleep in depressive pseudodementia [Buyasse] 568 (Je)
electroencephalographic sleep in mania [Hudson] 267 (Mr)
electroencephalographic sleep profiles in recurrent depression, longitudinal investigation [Kupfer] 678 (Jy)
reliable discrimination of elderly depressed and demented patients by electroencephalographic sleep data [Reynolds] 258 (Mr)
Electroshock Therapy see Electroconvulsive Therapy
Emergency Services, Psychiatric see Mental Health Services
Emotions
dose of fluphenazine, familial expressed emotion, and outcome in schizophrenia, results of 2-year controlled study [Hogarty] 797 (Se)
parental 'expressed emotion' as predictor of schizophrenic relapse [Parker] 806 (Se)
Employment Termination see Unemployment
Endocrine Glands
cyclic delta peaks during sleep, result of pulsatile endocrine process? (letter) [Feinberg] 1140 (De)
Environment
adoptee studies of psychiatric disorders (letter) [Donovan] (reply) [Kety] 875 (Se)
Enzyme Linked Immunosorbent Assay
antisomatostatin IgG in major depressive disorder, preliminary study with implications for autoimmune mechanism of depression [Roy] 924 (Oc)
Epidemiologic Methods
epidemiologic approaches to developmental psychopathology [Rutter] 486 (My)
epidemiology of obsessive-compulsive disorder in 5 US communities [Karno] 1094 (De)
estimates of prevalence of childhood maladjustment in community survey in Puerto Rico, use of combined measures [Bird] 1120 (De)
prevalence of psychiatric disorders in primary care practice [Barrett] 1100 (De)
psychiatric disorders in pediatric primary care, prevalence and risk factors [Costello] 1107 (De)
selection of controls for family studies, biases and implications [Tsuang] 1006 (No)
what is a case? food for thought for epidemiologists [Kendell] 374 (Ap)
what is a case? 45-year study of psychiatric impairment within college sample selected for mental health [Vaillant] 313 (Ap)
Epinephrine
cerebrospinal fluid and urinary biogenic amines in depressed patients and healthy controls [Davis] 705 (Au)
high correlations of norepinephrine, dopamine, and epinephrine and their major metabolite excretion rates [Linnoila] 701 (Au)
Esterases
association of autism, retinoblastoma, and reduced esterase D activity (letter) [Ritvo] 600 (Je)
Ethics, Medical
brains of Vogt collection (letter) [Rogerts] 774 (Au)
comment, on deaths of Ernst and Klaus H (letters) [Becker, Gershon] 774, 775 (Au)
Euthanasia
comment, on deaths of Ernst and Klaus H (letters) [Becker, Gershon] 774, 775 (Au)
Evaluation Studies, FDA Phase III see Clinical Trials
Evaluation Studies, FDA Phase IV see Clinical Trials
Extrapyramidal Tracts
who should receive clozapine? [Marder] 865 (Se)
Eye Movements
effect of neuroleptics and tardive dyskinesia on smooth-pursuit eye movement in chronic schizophrenics [Spohn] 833 (Se)
eye tracking dysfunction is associated with partial trisomy of chromosome 5 and schizophrenia (letter) [Iacono] 1140 (De)
single dominant gene can account for eye tracking dysfunctions and schizophrenia in offspring of discordant twins [Holzman] 641 (Jy)

F

Family
adoptee studies of psychiatric disorders (letter) [Donovan] (reply) [Kety] 875 (Se)
controlled family study of chronic psychoses, schizophrenia and schizoaffective disorder [Gershon] 328 (Ap)
dose of fluphenazine, familial expressed emotion, and outcome in schizophrenia, results of 2-year controlled study [Hogarty] 797 (Se)
familial aggregation of schizophrenia and schizophrenia spectrum disorders, evaluation of conflicting results [Kendler] 377 (Ap)
familial rates of affective disorder, report from National Institute of Mental Health Collaborative Study [Andreasen] 44:461 (My); correction, 45:776 (Au)
familial risk of dementia associated with biologic subtype of Alzheimer's disease [Zubenko] 889 (Oc)
family and genetic studies of affective disorders [Blehar] 289 (Mr)
family factors and course of bipolar affective disorder [Mikkowitz] 225 (Mr)
husbands' layoff and wives' mental health, prospective analysis [Penkower] 994 (No)
inpatient family intervention, randomized clinical trial, II. results at hospital discharge [Haas] 217 (Mr)
parental 'expressed emotion' as predictor of schizophrenic relapse [Parker] 806 (Se)
parental loss in childhood, its effect in adult life [Tennant] 1045 (No)
reliability of family history method for psychiatric diagnoses [Zimmerman] 320 (Ap)
selection of controls for family studies, biases and implications [Tsuang] 1006 (No)
siblings of disabled children, effects of chronic stress in family [Breslau] 44:1040 (De); correction, 45:196 (Fe)
twin studies and genetic models of schizophrenia (letter) [Levinson] 876, (reply) [Farmer] 877 (Se)
Family Health see Family
Family Life Cycles see Family
Family Relationships see Family
Fear
α_2-adrenergic receptor sensitivity in depression, plasma MHPG, behavioral, and cardiovascular responses to yohimbine [Heninger] 718 (Au)
blood gas changes and hypophosphatemia in lactate-induced panic (letters) [Bass, Griez] 95, 96, (reply) [Gorman] 96 (Ja)
carbon dioxide-induced anxiety, behavioral, physiologic, and biochemical effects of carbon dioxide in patients with panic disorders and healthy subjects [Woods] 43 (Ja)
cause and treatment of agoraphobia (letter) [Lelliott] 388, (reply) [Klein] 389 (Ap)
course of panic attacks and agoraphobia (letters) [Maier, Papeschi] 501, (reply) [Charney] 502 (My)
drug therapy for agoraphobia (letter) [Scott] (reply) [Klein] 387 (Ap)
hemodynamic, ventilatory, and biochemical responses of panic patients and normal controls with sodium lactate infusion and spontaneous panic attacks [Gaffney] 53 (Ja)
relative hypophosphatemia in patients with panic disorder (letter) [Balon] 294 (Mr)
ventilatory physiology of patients with panic disorder [Gorman] 31 (Ja)
Fenelzin see Phenelzine
Finland
adult schizophrenia following prenatal exposure to influenza epidemic [Mednick] 189 (Fe)
Firearms
risk factors for adolescent suicide, comparison of adolescent suicide victims with suicidal inpatients [Brent] 581 (Je)
Flufenazine see Fluphenazine
Fluphenazine
alprazolam augmentation of antipsychotic effects of fluphenazine in schizophrenic patients, preliminary results [Wolkowitz] 664 (Jy)
differential effect of low and conventional doses of fluphenazine on schizophrenic outpatients with good or poor information-processing abilities [Asarnow] 822 (Se)
dose of fluphenazine, familial expressed emotion, and outcome in schizophrenia, results of 2-year controlled study [Hogarty] 797 (Se)
neuroleptic plasma level may predict response in patients who meet criterion for improvement (letter) [Levinson] 878 (Se)
Follow-Up Studies
course of panic attacks and agoraphobia (letters) [Maier, Papeschi] 501, (reply) [Charney] 502 (My)
excess mortality among formerly hospitalized child psychiatric patients [Kuperman] 277 (Mr)
family factors and course of bipolar affective disorder [Mikkowitz] 225 (Mr)
hospital discharge status and long-term outcome for patients with schizophrenia, schizoaffective disorder, borderline personality disorder, and unipolar affective disorder [McGlashan] 363 (Ap)
hyperactive boys almost grown up, II. status of subjects without mental disorder [Mannuzza] 13 (Ja)
predicting hospital discharge status for patients with schizophrenia, schizoaffective disorder, borderline personality disorder, and unipolar affective disorder [Heinssen] 353 (Ap)
selection of controls for family studies, biases and implications [Tsuang] 1006 (No)
siblings of disabled children, effects of chronic stress in family [Breslau] 44:1040 (De); correction, 45:196 (Fe)
Fragile Syndrome see Sex Chromosome Abnormalities
Fraud see Crime
Frontal Lobe
computed tomographic evidence for generalized sulcal and ventricular enlargement in schizophrenia [Pfefferbaum] 633 (Jy)

G

Gambling see Risk-Taking
Gender Identity see Identification (Psychology)
General Practitioners see Physicians, Family
Genetic Marker
biologic markers, genetics, and Alzheimer's disease [Small] 945 (Oc)
Genetics, Human see Genetics, Medical
Genetics, Medical see also Hereditary Diseases
adoptee studies of psychiatric disorders (letter) [Donovan] (reply) [Kety] 875 (Se)
autism and genetics, decade of research [Smalley] 953 (Oc)
biologic markers, genetics, and Alzheimer's disease [Small] 945 (Oc)
eye tracking dysfunction is associated with partial trisomy of chromosome 5 and schizophrenia (letter) [Iacono] 1140 (De)
family and genetic studies of affective disorders [Blehar] 289 (Mr)
heritability of schizophrenia and schizoaffective disorder, family study [Coryell] 323 (Ap)
morbid risk in first-degree relatives of persons with Alzheimer's disease (letter) [Heston] 97, (reply) [Moha] 98 (Ja)
outcome and familial psychopathology in schizophrenia [Kendler] 338 (Ap)
psychiatric disability in female carriers of fragile X chromosome [Reiss] 25 (Ja)
simultaneous evaluation of multiple markers of ethanol/placebo challenges in sons of alcoholics and controls [Schuckit] 211 (Mr)
single dominant gene can account for eye tracking dysfunctions and schizophrenia in offspring of discordant twins [Holzman] 641 (Jy)
twin studies and genetic models of schizophrenia (letter) [Levinson] 876, (reply) [Farmer] 877 (Se)
Genotype
neurodevelopmental model of schizophrenia (letters) [King, Lewine, Murray] 1051, 1052, (reply) [Weinberger] 1053 (No)
Geriatrics
effects of acute scopolamine in geriatric depression [Newhouse] 906 (Oc)
increased activity and phase delay in circadian motility rhythms in geriatric depression, preliminary observations [Teicher] 913 (Oc)
marked reduction in number of platelet-tritiated imipramine binding sites in geriatric depression [Nemeroff] 919 (Oc)
Glucose
effect of neuroleptics on altered cerebral glucose metabolism in schizophrenia [Szechtman] 523 (Je)
Glycols
α_2-adrenergic receptor sensitivity in depression, plasma MHPG, behavioral, and cardiovascular responses to yohimbine [Heninger] 718 (Au)
carbon dioxide-induced anxiety, behavioral, physiologic, and biochemical effects of carbon dioxide in patients with panic disorders and healthy subjects [Woods] 43 (Ja)
cerebrospinal fluid and urinary biogenic amines in depressed patients and healthy controls [Davis] 705 (Au)
diurnal variation in plasma homovanillic acid level persists but variation in 3-methoxy-4-hydroxyphenylglycol level is abolished under constant conditions [Sack] 162 (Fe)
dopamine metabolism and disposition in schizophrenic patients, studies using debrisoquin [Maas] 553 (Je)
plasma monoamine metabolites in psychotic disorders [Bowers] 595 (Je)
plasma 3-methoxy-4-hydroxyphenylglycol changes associated with clinical state and schizophrenic subtype [Ko] 842 (Se)
sensation seeking and behavior disorders (letter) [Zuckerman] 502, (reply) [Cloninger] 503 (My)
Gonads
sex chromosome anomalies, hormones, and sexuality [Schiavi] 19 (Ja)

H

Haloperidol
central D2-dopamine receptor occupancy in schizophrenic patients treated with antipsychotic drugs [Farde] 71 (Ja)
persistence of haloperidol in brain (letter) [Cohen] 879 (Se)
plasma homovanillic acid as predictor of response to neuroleptics [Davila] 564 (Je)
Health Insurance for Aged and Disabled, Title 18
simulating policy options for psychiatric care in general hospitals under Medicare's PPS [Freiman] 1032 (No)
toward a fairer prospective payment system [Essock] 1041 (No)
use of specialty psychiatric settings in constructing DRGs [Taube] 1037 (No)
Health Maintenance Organizations
psychiatric disorders in pediatric primary care, prevalence and risk factors [Costello] 1107 (De)
Health Services and Mental Health Administration (US) see United States Alcohol, Drug Abuse and Mental Health Administration
Health Surveys
imipramine treatment for chronic depression [Koesis] 253 (Mr)
San Diego Suicide Study, III. relationships between diagnoses and stressors [Rich] 589 (Je)
validity of self-report questionnaire for diagnosing major depressive disorder [Zimmerman] 738 (Au)
Heart Ventricle
computed tomographic evidence for generalized sulcal and ventricular enlargement in schizophrenia [Pfefferbaum] 633 (Jy)
Hematocrit
abnormal resting regional cerebral blood flow patterns and their correlates in schizophrenia [Mathew] 542 (Je)
Hemodynamics
hemodynamic, ventilatory, and biochemical responses of panic patients and normal controls with sodium lactate infusion and spontaneous panic attacks [Gaffney] 53 (Ja)
Hepatitis
alprazolam in agoraphobia with panic attacks and panic disorder, results of multicenter trial, II. patient acceptance, side effects, and safety [Noyes] 423 (My)
Hereditary Diseases see also Genetics, Medical
adoptee studies of psychiatric disorders (letter) [Donovan] (reply) [Kety] 875 (Se)
familial aggregation of schizophrenia and schizophrenia spectrum disorders, evaluation of conflicting results [Kendler] 377 (Ap)
familial rates of affective disorder, report from National Institute of Mental Health Collaborative Study [Andreasen] 44:461 (My); correction, 45:776 (Au)
familial risk of dementia associated with biologic subtype of Alzheimer's disease [Zubenko] 889 (Oc)
family-genetic study of dementia of Alzheimer type [Martin] 894 (Oc)

methylphenidate-induced information processing dysfunction in nonschizophrenic patients [Braff] 827 (Se)
twin studies and genetic models of schizophrenia (letter) [Levinson] 876, (reply) [Farmer] 877 (Se)

Hippocampus
impairments on neuropsychologic tests of temporohippocampal and frontohippocampal functions and word fluency in remitting schizophrenia and affective disorders [Gruzelier] 623 (Jy)

Histology
intracerebral inoculation of experimental animals with brain tissue from patients with schizophrenia, failure to observe consistent or specific behavioral and neuropathological effects [Kaufmann] 648 (Jy)

HIV
prevalence of psychiatric disorders among men infected with human immunodeficiency virus, controlled study [Atkinson] 859 (Se)

Homeless Persons
alcoholism among homeless adults in inner city of Los Angeles [Koegel] 1011 (No)
prevalence of specific psychiatric disorders among homeless individuals in inner city of Los Angeles [Koegel] 1085 (De)

Homosexuality
prevalence of psychiatric disorders among men infected with human immunodeficiency virus, controlled study [Atkinson] 859 (Se)

Homovanillic Acid
alprazolam augmentation of antipsychotic effects of fluphenazine in schizophrenic patients, preliminary results [Wolkowitz] 664 (Jy)
bupropion in depression, I. biochemical effects and clinical response, 139; II. role of metabolites in clinical outcome [Golden] 145 (Fe)
cerebrospinal fluid and urinary biogenic amines in depressed patients and healthy controls [Davis] 705 (Au)
comparison of plasma homovanillic acid concentrations in schizophrenic patients and normal controls [Davidson] 561 (Je)
diurnal variation in plasma homovanillic acid level persists but variation in 3-methoxy-4-hydroxyphenylglycol level is abolished under constant conditions [Sack] 162 (Fe)
dopamine metabolism and disposition in schizophrenic patients, studies using debrisoquin [Maas] 553 (Je)
physiological dysfunction of dorsolateral prefrontal cortex in schizophrenia, III. new cohort and evidence for monoaminergic mechanism [Weinberger] 609 (Jy)
plasma homovanillic acid as predictor of response to neuroleptics [Davila] 564 (Je)
plasma monoamine metabolites in psychotic disorders [Bowers] 595 (Je)
sensation seeking and behavior disorders (letter) [Zuckerman] 502, (reply) [Cloninger] 503 (My)

Hospitals
use of specialty psychiatric settings in constructing DRGs [Taube] 1037 (No)

Hospitals, General
simulating policy options for psychiatric care in general hospitals under Medicare's PPS [Freiman] 1032 (No)

Hospitals, Psychiatric
inpatient family intervention, randomized clinical trial, II. results at hospital discharge [Haas] 217 (Mr)
simulating policy options for psychiatric care in general hospitals under Medicare's PPS [Freiman] 1032 (No)

Human Experimentation
brains of Vogt collection (letter) [Bogerts] 774 (Au)
comment, on deaths of Ernst and Klaus H (letters) [Becker, Gershon] 776, 775 (Au)

Hydrazines
efficacy study of isocarboxazid and placebo in depression, and its relationship to depressive nosology [Davidson] 120 (Fe)

Hydrochloric Acid
imipramine treatment for chronic depression [Kocsis] 253 (Mr)

Hydrocortisone
carbon dioxide-induced anxiety, behavioral, physiologic, and biochemical effects of carbon dioxide in patients with panic disorders and healthy subjects [Woods] 43 (Ja)
increased activity and phase delay in circadian motility rhythms in geriatric depression, preliminary observations [Teicher] 913 (Oc)
marked reduction in number of platelet-tritiated imipramine binding sites in geriatric depression [Nemeroff] 919 (Oc)
norepinephrine and its metabolites in cerebrospinal fluid, plasma, and urine, relationship to hypothalamic-pituitary-adrenal axis function in depression [Roy] 849 (Se)
serotonergic responsivity in obsessive-compulsive disorder, effects of chronic clomipramine treatment [Zohar] 167 (Fe)
simultaneous evaluation of multiple markers of ethanol/placebo challenges in sons of alcoholics and controls [Schuckit] 211 (Mr)

Hydrogen Chloride see **Hydrochloric Acid**

Hydroxyindoleacetic Acid
cerebrospinal fluid and urinary biogenic amines in depressed patients and healthy controls [Davis] 705 (Au)
physiological dysfunction of dorsolateral prefrontal cortex in schizophrenia, III. new cohort and evidence for monoaminergic mechanism [Weinberger] 609 (Jy)

Hyperactivity, Motor see **Hyperkinesis**

Hypercorticism see **Adrenal Gland Hyperfunction**

Hyperkinesis
hyperactive boys almost grown up, II. status of subjects without mental disorder [Mannuzza] 13 (Ja)

Hypernatremia
hemodynamic, ventilatory, and biochemical responses of panic patients and normal controls with sodium lactate infusion and spontaneous panic attacks [Gaffney] 53 (Ja)

Hyperventilation
blood gas changes and hypophosphatemia in lactate-induced panic (letters) [Bass, Griez] 95, 96, (reply) [Gorman] 96 (Ja)
ventilatory physiology of patients with panic disorder [Gorman] 31 (Ja)

Hypophosphatemia, Familial
blood gas changes and hypophosphatemia in lactate-induced panic (letters) [Bass, Griez] 95, 96, (reply) [Gorman] 96 (Ja)
relative hypophosphatemia in patients with panic disorder (letter) [Balon] 294 (Mr)

Hypophysectomy
effect of ketoconazole on hypophysectomized, hypercortisolemic, psychotically depressed woman (letter) [Ravaris] 966 (Oc)

Hypothalamo-Hypophyseal System
early parental loss and development of psychopathology [Breier] 987 (No)
norepinephrine and its metabolites in cerebrospinal fluid, plasma, and urine, relationship to hypothalamic-pituitary-adrenal axis function in depression [Roy] 849 (Se)
reduced corticotropin releasing factor binding sites in frontal cortex of suicides [Nemeroff] 577 (Je)

Hypothalmic Hormones
cyclic delta peaks during sleep, result of pulsatile endocrine process? (letter) [Feinberg] 1140 (De)

I

Identification (Psychology)
sex chromosome anomalies, hormones, and sexuality [Schiavi] 19 (Ja)

IgG
antisomatostatin IgG in major depressive disorder, preliminary study with implications for autoimmune mechanism of depression [Roy] 924 (Oc)

Imipramine
alprazolam in agoraphobia with panic attacks and panic disorder, results of multicenter trial, II. patient acceptance, side effects, and safety [Noyes] 423 (My)
antidepressant specificity in atypical depression [Liebowitz] 129 (Fe)
drug therapy for agoraphobia (letter) [Scott] (reply) [Klein] 387 (Ap)
imipramine treatment for chronic depression [Kocsis] 253 (Mr)
marked reduction in number of platelet-tritiated imipramine binding sites in geriatric depression [Nemeroff] 919 (Oc)
overview of cross-national collaborative panic study [Klerman] 407 (My)
reduced corticotropin releasing factor binding sites in frontal cortex of suicides [Nemeroff] 577 (Je)

Immunohistochemistry
intracerebral inoculation of experimental animals with brain tissue from patients with schizophrenia, failure to observe consistent or specific behavioral and neuropathological effects [Kaufmann] 648 (Jy)

Immunosuppression
metabolic stress produces rapid immunosuppression in humans (letter) [Breier] **44**:1108 (De); correction **45**:68 (Ja)

Indians, North American
prevalence of specific psychiatric disorders among homeless individuals in inner city of Los Angeles [Koegel] 1085 (De)

Infection
causes of death in *DSM-III* schizophrenics and other psychotics (atypical group), comparison with general population [Buda] 283 (Mr)

Influenza Viruses see **Orthomyxoviridae**

Information Systems
meaning of full disclosure, collegial trust in science [Freedman] 689 (Jy)

Infusions, Intravenous
suspiciousness induced by 4-hour intravenous infusions of cocaine, preliminary findings [Sherer] 673 (Jy)

Inpatients see **Patients**

International Cooperation
composite international diagnostic interview, epidemiologic instrument suitable for use in conjunction with different diagnostic systems and in different cultures [Robins] 1069 (De)

Interview, Psychological
composite international diagnostic interview, epidemiologic instrument suitable for use in conjunction with different diagnostic systems and in different cultures [Robins] 1069 (De)
diagnosing personality disorder in depressed patients, comparison of patient and informant interviews [Zimmerman] 733 (Au)
epidemiology of obsessive-compulsive disorder in 5 US communities [Karno] 1094 (De)
reliability of telephone interview in diagnosing anxiety disorders [Paulsen] 62 (Ja)
structured interview guide for Hamilton depression rating scale [Williams] 742 (Au)
value of structured clinical interviews (letter) [Maier] 963 (Oc)

Involuntary Commitment see **Commitment of Mentally Ill**

Iodine Radioisotopes
lymphocyte β-adrenergic receptor modification in bulimia [Buckholtz] 479 (My)

Iowa
excess mortality among formerly hospitalized child psychiatric patients [Kuperman] 277 (Mr)

Isocarboxazid
efficacy study of isocarboxazid and placebo in depression, and its relationship to depressive nosology [Davidson] 120 (Fe)

Isoproterenol
blunted β-adrenergic responsivity of peripheral blood mononuclear cells in endogenous depression, isoproterenol dose-response studies [Halper] 241 (Mr)
lymphocyte β-adrenergic receptor modification in bulimia [Buckholtz] 479 (My)

Isoquinolines
dopamine metabolism and disposition in schizophrenic patients, studies using debrisoquin [Maas] 553 (Je)

K

Ketoconazole
effect of ketoconazole on hypophysectomized, hypercortisolemic, psychotically depressed woman (letter) [Ravaris] 966 (Oc)

Ketones
antidepressants reduce whole-body norepinephrine turnover while enhancing 6-hydroxymelatonin output [Golden] 150 (Fe)

L

Lactates
hemodynamic, ventilatory, and biochemical responses of panic patients and normal controls with sodium lactate infusion and spontaneous panic attacks [Gaffney] 53 (Ja)
relative hypophosphatemia in patients with panic disorder (letter) [Balon] 294 (Mr)

Legislation
civil commitment in psychiatric emergency room, I. assessment of dangerousness by emergency room clinicians [Segal] 748; II. mental disorder indicators and 3 dangerousness criteria [Segal] 753; III. disposition as function of mental disorder and dangerousness indicators [Segal] 759 (Au)
limitations on psychiatrists' discretionary civil commitment authority by Stone and dangerousness criteria [Hoge] 764 (Au)

Length of Stay
inpatient family intervention, randomized clinical trial, II. results at hospital discharge [Haas] 217 (Mr)
prospective study of delirium and prolonged hospital stay, exploratory study [Thomas] 937 (Oc)
use of specialty psychiatric settings in constructing DRGs [Taube] 1037 (No)

Lenticular Nucleus see **Corpus Striatum**

Leukocytes, Mononuclear
blunted β-adrenergic responsivity of peripheral blood mononuclear cells in endogenous depression, isoproterenol dose-response studies [Halper] 241 (Mr)

Lithium
complicated mania, comorbidity and immediate outcome in treatment of mania [Black] 232 (Mr)
electroconvulsive treatment compared with lithium in management of manic states [Small] 727 (Au)
family factors and course of bipolar affective disorder [Miklowitz] 225 (Mr)
is 'lithium carbonate' editorial dictate? (letter) [Schou] (reply) [Freedman] 298 (Mr)
lithium augmentation of antidepressant treatment, partially due to effect on cholinergic mechanism? (letter) [Dilsaver] 96 (Ja)
prescribing of psychotropic medication by primary care physicians and psychiatrists [Beardsley] 1117 (De)

Longitudinal Studies
electroencephalographic sleep profiles in recurrent depression, longitudinal investigation [Kupfer] 678 (Jy)
plasma 3-methoxy-4-hydroxyphenylglycol changes associated with clinical state and schizophrenic subtype [Ko] 842 (Se)

Lorazepam
effects of acute scopolamine in geriatric depression [Newhouse] 906 (Oc)

Los Angeles
alcoholism among homeless adults in inner city of Los Angeles [Koegel] 1011 (No)
prevalence of specific psychiatric disorders among homeless individuals in inner city of Los Angeles [Koegel] 1085 (De)

Lymphocytes
lymphocyte β-adrenergic receptor modification in bulimia [Buckholtz] 479 (My)
metabolic stress produces rapid immunosuppression in humans (letter) [Breier] **44**:1108 (De); correction **45**:68 (Ja)

M

Magnetic Resonance Imaging
quantitative neuroanatomy in schizophrenia, controlled magnetic resonance imaging study [Kelsoe] 533 (Je)

Mania see **Manic Disorder**

Manic-Depressive Psychosis see **Bipolar Disorders**

Manic Disorder
complicated mania, comorbidity and immediate outcome in treatment of mania [Black] 232 (Mr)
electroconvulsive treatment compared with lithium in management of manic states [Small] 727 (Au)
electroencephalographic sleep in mania [Hudson] 267 (Mr)

Marker, Genetic see **Genetic Marker**

Massachusetts
limitations on psychiatrists' discretionary civil commitment authority by Stone and dangerousness criteria [Hoge] 764 (Au)

Maternal-Fetal Exchange
adult schizophrenia following prenatal exposure to influenza epidemic [Mednick] 189 (Fe)

Mathematics
partial solution to base rate problem of κ statistic (letter) [Stewart] 504 (My)

Medical Records
controlled family study of chronic psychoses, schizophrenia and schizoaffective disorder [Gershon] 328 (Ap)

Melancholia see Depressive Disorder
Memory Disorders
family-genetic study of dementia of Alzheimer type [Martin] 894 (Oc)
impairments on neuropsychologic tests of temporohippocampal and frontohippocampal functions and word fluency in remitting schizophrenia and affective disorders [Gruzelier] 623 (Jy)
Mental Disorders
alcoholism among homeless adults in inner city of Los Angeles [Koegel] 1011 (No)
civil commitment in psychiatric emergency room, I. assessment of dangerousness by emergency room clinicians [Segal] 748; II. mental disorder indicators and 3 dangerousness criteria [Segal] 753; III. disposition as function of mental disorder and dangerousness indicators [Segal] 759 (Au)
civil commitment, relationship between perceived dangerousness and mental illness [Mills] 770 (Au)
composite international diagnostic interview, epidemiologic instrument suitable for use in conjunction with different diagnostic systems and in different cultures [Robins] 1069 (De)
having a dream, research strategy for *DSM-IV* [Spitzer] 871 (Se)
hyperactive boys almost grown up, II. status of subjects without mental disorder [Mannuzza] 13 (Ja)
limitations on psychiatrists' discretionary civil commitment authority by Stone and dangerousness criteria [Hoge] 764 (Au)
one-month prevalence of mental disorders in United States, based on 5 epidemiologic catchment area sites [Regier] 977 (No)
prevalence of psychiatric disorders in patients with alcohol and other drug problems [Ross] 1023 (No)
prevalence of specific psychiatric disorders among homeless individuals in inner city of Los Angeles [Koegel] 1065 (De)
Mental Health Services
civil commitment in psychiatric emergency room, I. assessment of dangerousness by emergency room clinicians [Segal] 748; II. mental disorder indicators and 3 dangerousness criteria [Segal] 753; III. disposition as function of mental disorder and dangerousness indicators [Segal] 759 (Ru)
civil commitment, relationship between perceived dangerousness and mental illness [Mills] 770 (Au)
limitations on psychiatrists' discretionary civil commitment authority by Stone and dangerousness criteria [Hoge] 764 (Au)
Mental Hospitals see Hospitals, Psychiatric
Mental Hygiene Services see Mental Health Services
Mental Retardation
autism and genetics, decade of research [Smalley] 953 (Oc)
excess mortality among formerly hospitalized child psychiatric patients [Kuperman] 277 (Mr)
psychiatric disability in female carriers of fragile X chromosome [Reiss] 25 (Ja)
Metabolism
cyclic delta peaks during sleep, result of pulsatile endocrine process? (letter) [Feinberg] 1140 (De)
effect of neuroleptics on altered cerebral glucose metabolism in schizophrenia [Szechtman] 523 (Je)
high intercorrelations among urinary outputs of norepinephrine and its major metabolites, replication in depressed patients and controls [Roy] 158 (Fe)
norepinephrine and its metabolites in cerebrospinal fluid, plasma, and urine, relationship to hypothalamic-pituitary-adrenal axis function in depression [Roy] 849 (Se)
Metanephrine see Glycols
Methanol see Alcohol, Ethyl
3-Methoxy-4-Hydroxyphenylethanol see Catechols
Methoxyhydroxyphenylglycol see Glycols
Methylarecaidin see Arecoline
Methylphenidate
hyperactive boys almost grown up, III. methylphenidate effects on ultimate height [Klein] 1181 (De)
methylphenidate and growth in hyperactive children, controlled withdrawal study [Klein] 1127 (De)
methylphenidate-induced information processing dysfunction in nonschizophrenic patients [Braff] 827 (Se)
MOPG see Glycols
Monkeys, New World see Cebidae
Monkeys, Old World see Cercopithecidae
Monoamine Oxidase
antidepressants reduce whole-body norepinephrine turnover while enhancing 6-hydroxymelatonin output [Golden] 150 (Fe)
blunted β-adrenergic responsivity of peripheral blood mononuclear cells in endogenous depression, isoproterenol dose-response' studies [Halper] 241 (Mr)
high correlations of norepinephrine, dopamine, and epinephrine and their major metabolite excretion rates [Linnoila] 701 (Au)
methylphenidate-induced information processing dysfunction in nonschizophrenic patients [Braff] 827 (Se)
pathological gambling, psychobiological study [Roy] 369 (Ap)
physiological dysfunction of dorsolateral prefrontal cortex in schizophrenia, III. new cohort and evidence for monoaminergic mechanism [Weinberger] 609; IV. further evidence for regional and behavioral specificity [Berman] 616 (Jy)
plasma monoamine metabolites in psychotic disorders [Bowers] 595 (Je)
sensation seeking and behavior disorders (letter) [Zuckerman] 502, (reply) [Cloninger] 503 (My)
Monoamine Oxidase Inhibitors
antidepressant specificity in atypical depression [Liebowitz] 129 (Fe)
efficacy study of isocarboxazid and placebo in depression, and its relationship to depressive nosology [Davidson] 120 (Fe)
phenelzine vs placebo in 50 patients with bulimia [Walsh] 471 (My)
where are those new antidepressants we were promised? [Cole] 193 (Fe)
Mononuclear Leukocytes see Leukocytes, Mononuclear
Mortality
causes of death in *DSM-III* schizophrenics and other psychotics (atypical group), comparison with general population [Buda] 283 (Mr)
excess mortality among formerly hospitalized child psychiatric patients [Kuperman] 277 (Mr)
Myxoviruses see Orthomyxoviridae

N

Neoplasms
causes of death in *DSM-III* schizophrenics and other psychotics (atypical group), comparison with general population [Buda] 283 (Mr)
Neuroanatomy
asymmetries in hemispheric control of attention in schizophrenia [Posner] 814 (Se)
quantitative neuroanatomy in schizophrenia, controlled magnetic resonance imaging study [Kelsoe] 533 (Je)
Neuroleptics see Tranquilizing Agents, Major
Neurology
intracerebral inoculation of experimental animals with brain tissue from patients with schizophrenia, failure to observe consistent or specific behavioral and neuropathological effects [Kaufmann] 648 (Jy)
Neuropeptides
social zeitgebers and biological rhythms, unified approach to understanding etiology of depression [Ehlers] 948 (Oc)
Neuropsychological Tests
impairments on neuropsychologic tests of temporohippocampal and frontohippocampal functions and word fluency in remitting schizophrenia and affective disorders [Gruzelier] 623 (Jy)
Neuropsychology
computed tomographic evidence for generalized sulcal and ventricular enlargement in schizophrenia [Pfefferbaum] 633 (Jy)
Neuroregulators
diurnal variation in plasma homovanillic acid level persists but variation in 3-methoxy-4-hydroxyphenylglycol level is abolished under constant conditions [Sack] 162 (Fe)
sensation seeking and behavior disorders (letter) [Zuckerman] 502, (reply) [Cloninger] 503 (My)
serotonin function in obsessive-compulsive disorder, comparison of effects of tryptophan and *m*-chlorophenylpiperazine in patients and healthy subjects [Charney] 177 (Fe)
Neurosecretory Systems
early parental loss and development of psychopathology [Breier] 987 (No)
Neuroses, Anxiety see Anxiety Disorders
Neurosis, Depressive see Depressive Disorder
Neurosis, Post-Traumatic see Stress Disorders, Post-traumatic
Neurotic Disorders
clomipramine treatment of agoraphobic women, 8-week controlled trial [Johnston] 453 (My)
Neurotransmitters see Neuroregulators
Norepinephrine
antidepressants reduce whole-body norepinephrine turnover while enhancing 6-hydroxymelatonin output [Golden] 150 (Fe)
bupropion in depression, I. biochemical effects and clinical response [Golden] 139 (Fe)
carbon dioxide-induced anxiety, behavioral, physiologic, and biochemical effects of carbon dioxide in patients with panic disorders and healthy subjects [Woods] 43 (Ja)
cerebrospinal fluid and urinary biogenic amines in depressed patients and healthy controls [Davis] 705 (Au)
diurnal variation in plasma homovanillic acid level persists but variation in 3-methoxy-4-hydroxyphenylglycol level is abolished under constant conditions [Sack] 162 (Fe)
dopamine metabolism and disposition in schizophrenic patients, studies using debrisoquin [Maas] 553 (Je)
high correlations of norepinephrine, dopamine, and epinephrine and their major metabolite excretion rates [Linnoila] 701 (Au)
high intercorrelations among urinary outputs of norepinephrine and its major metabolites, replication in depressed patients and controls [Roy] 158 (Fe)
lymphocyte β-adrenergic receptor modification in bulimia [Buckholtz] 479 (My)
norepinephrine and its metabolites in cerebrospinal fluid, plasma, and urine, relationship to hypothalamic-pituitary-adrenal axis function in depression [Roy] 849 (Se)
pathological gambling, psychobiological study [Roy] 369 (Ap)
plasma 3-methoxy-4-hydroxyphenylglycol changes associated with clinical state and schizophrenic subtype [Ko] 842 (Se)
sensation seeking and behavior disorders (letter) [Zuckerman] 502, (reply) [Cloninger] 503 (My)
ventilatory physiology of patients with panic disorder [Gorman] 31 (Ja)
Nortriptyline
how effective and safe is continuation therapy in elderly depressed patients, factors affecting relapse rate [Georgotas] 929 (Oc)
Nuclear Family see Family

O

Obsessive-Compulsive Disorder
epidemiology of obsessive-compulsive disorder in 5 US communities [Karno] 1094 (De)
serotonergic responsivity in obsessive-compulsive disorder, effects of chronic clomipramine treatment [Zohar] 167 (Fe)
serotonin function in obsessive-compulsive disorder, comparison of effects of tryptophan and *m*-chlorophenylpiperazine in patients and healthy subjects [Charney] 177 (Fe)
Opportunistic Infections
metabolic stress produces rapid immunosuppression in humans (letter) [Breier] 44:1108 (De); correction 45:68 (Ja)
Orthomyxoviridae
adult schizophrenia following prenatal exposure to influenza epidemic [Mednick] 189 (Fe)
Orthomyxovirusee Type C see Orthomyxoviridae
Outpatients see Patients
Oxazepam
methylphenidate-induced information processing dysfunction in nonschizophrenic patients [Braff] 827 (Se)

P

Pancreas
prevalence of major depression, simple phobia, and other psychiatric disorders in patients with long-standing type I diabetes mellitus [Popkin] 64 (Ja)
Panic see Fear
Paradoxical Sleep see Sleep, REM
Paranoid Disorders
suspiciousness induced by 4-hour intravenous infusions of cocaine, preliminary findings [Sherer] 673 (Jy)
Parasympatholytics
effects of acute scopolamine in geriatric depression [Newhouse] 906 (Oc)
Parasympathomimetics
lithium augmentation of antidepressant treatment, partially due to effect on cholinergic mechanism? (letter) [Dilsaver] 96 (Ja)
Parents
early parental loss and development of psychopathology [Breier] 987 (No)
parental 'expressed emotion' as predictor of schizophrenic relapse [Parker] 806 (Se)
parental loss in childhood, its effect in adult life [Tennant] 1045 (No)
Parkinson Disease
prefrontal-type cognitive deficits and chronic psychiatric conditions (letter) [Wong] (reply) [Goldberg] 1054 (No)
Pathology
intracerebral inoculation of experimental animals with brain tissue from patients with schizophrenia, failure to observe consistent or specific behavioral and neuropathological effects [Kaufmann] 648 (Jy)
pathologic heterogeneity of Alzheimer's disease (letter) [Mann] 962, (reply) [Bondareff] 963 (Oc)
Patient Discharge
hospital discharge status and long-term outcome for patients with schizophrenia, schizoaffective disorder, borderline personality disorder, and unipolar affective disorder [McGlashan] 363 (Ap)
predicting hospital discharge status for patients with schizophrenia, schizoaffective disorder, borderline personality disorder, and unipolar affective disorder [Heinssen] 353 (Ap)
Patients
comorbidity of borderline personality disorder [Fyer] 348 (Ap)
differential effect of low and conventional doses of fluphenazine on schizophrenic outpatients with good or poor information-processing abilities [Asarnow] 822 (Se)
excess mortality among formerly hospitalized child psychiatric patients [Kuperman] 277 (Mr)
pharmacotherapy for patients with borderline personality disorder (letter) [Goldberg] 195, (reply) [Gunderson] 196 (Fe)
risk factors for adolescent suicide, comparison of adolescent suicide victims with suicidal inpatients [Brent] 581 (Je)
Peer Review
request for retraction (letters) [Ferguson, Davidson, Poling] 685, 686, (editorial comment) [Freedman] 686 (Jy)
toward a fairer prospective payment system [Essock] 1041 (No)
Personality Disorder, Schizotypal see Schizotypal Personality Disorder
Personality Disorders
comorbidity of borderline personality disorder [Fyer] 348 (Ap)
controlled family study of chronic psychoses, schizophrenia and schizoaffective disorder [Gershon] 328 (Ap)
diagnosing personality disorder in depressed patients, comparison of patient and informant interviews [Zimmerman] 733 (Au)
familial aggregation of schizophrenia and schizophrenia spectrum disorders, evaluation of conflicting results [Kendler] 377 (Ap)
hospital discharge status and long-term outcome for patients with schizophrenia, schizoaffective disorder, borderline personality disorder, and unipolar affective disorder [McGlashan] 363 (Ap)
pharmacotherapy for patients with borderline personality disorder (letter) [Goldberg] 195, (reply) [Gunderson] 196 (Fe)
pharmacotherapy of borderline personality disorder, alprazolam, carbamazepine, trifluoperazine, and tranylcypromine [Cowdry] 111 (Fe)
predicting hospital discharge status for patients with schizophrenia, schizoaffective disorder, borderline personality disorder, and unipolar affective disorder [Heinssen] 353 (Ap)
sensation seeking and behavior disorders (letter) [Zuckerman] 502, (reply) [Cloninger] 503 (My)

PERSPECTIVES
significance of neuroleptic dose and plasma level in pharmacological treatment of psychoses [Baldessarini] 79 (Ja)
Pharmacotherapy see Drug Therapy
Phenelzine
antidepressant specificity in atypical depression [Liebowitz] 129 (Fe)
how effective and safe is continuation therapy in elderly depressed patients, factors affecting relapse rate [Georgotas] 929 (Oc)
imipramine treatment for chronic depression [Kocsis] 253 (Mr)
phenelzine vs placebo in 50 patients with bulimia [Walsh] 471 (My)
Phobic Disorders
α_2-adrenergic receptor sensitivity in depression, plasma MHPG, behavioral, and cardiovascular responses to yohimbine [Heninger] 718 (Au)
alprazolam in panic disorder and agoraphobia, results from multicenter trial, I. efficacy in short-term treatment [Ballenger] 413; II. patient acceptance, side effects, and safety [Noyes] 423; III. discontinuation effects [Pecknold] 429 (My)
behavioral inhibition in children of parents with panic disorder and agoraphobia, controlled study [Rosenbaum] 463 (My)
cause and treatment of agoraphobia (letter) [Lelliott] 388, (reply) [Klein] 389 (Ap)
clomipramine treatment of agoraphobic women, 8-week controlled trial [Johnston] 453 (My)
composite international diagnostic interview, epidemiologic instrument suitable for use in conjunction with different diagnostic systems and in different cultures [Robins] 1069 (De)
course of panic attacks and agoraphobia (letters) [Maier, Papeschi] 501, (reply) [Charney] 502 (My)
drug therapy for agoraphobia (letter) [Scott] (reply) [Klein] 387 (Ap)
overview of cross-national collaborative panic study [Klerman] 407 (My)
prevalence of major depression, simple phobia, and other psychiatric disorders in patients with long-standing type I diabetes mellitus [Popkin] 64 (Ja)
prevalence of psychiatric disorders in patients with alcohol and other drug problems [Ross] 1023 (No)
reliability of telephone interview in diagnosing anxiety disorders [Paulsen] 62 (Ja)
secondary depression in panic disorder and agoraphobia, I. frequency, severity, and response to treatment [Lesser] 437 (My)
ventilatory physiology of patients with panic disorder [Gorman] 31 (Ja)
Phosphates
relative hypophosphatemia in patients with panic disorder (letter) [Balon] 294 (Mr)
Physicians
prescribing of psychotropic medication by primary care physicians and psychiatrists [Beardsley] 1117 (De)
Physicians, Family
prescribing of psychotropic medication by primary care physicians and psychiatrists [Beardsley] 1117 (De)
prevalence of psychiatric disorders in primary care practice [Barrett] 1100 (De)
Pituitary-Adrenal System
early parental loss and development of psychopathology [Breier] 987 (No)
norepinephrine and its metabolites in cerebrospinal fluid, plasma, and urine, relationship to hypothalamic-pituitary- adrenal axis function in depression [Roy] 849 (Se)
reduced corticotropin releasing factor binding sites in frontal cortex of suicides [Nemeroff] 577 (Je)
Pituitary Gland
sex chromosome anomalies, hormones, and sexuality [Schiavi] 19 (Ja)
Placebos
alprazolam in panic disorder and agoraphobia, results from multicenter trial, I. efficacy in short-term treatment [Ballenger] 413; II. patient acceptance, side effects, and safety [Noyes] 423; III. discontinuation effects [Pecknold] 429 (My)
antidepressant specificity in atypical depression [Liebowitz] 129 (Fe)
efficacy study of iaocarboxazid and placebo in depression, and its relationship to depressive nosology [Davidson] 120 (Fe)
overview of cross-national collaborative panic study [Klerman] 407 (My)
phenelzine vs placebo in 50 patients with bulimia [Walsh] 471 (My)
simultaneous evaluation of multiple markers of ethanol/placebo challenges in sons of alcoholics and controls [Schuckit] 211 (Mr)
suspiciousness induced by 4-hour intravenous infusions of cocaine, preliminary findings [Sherer] 673 (Jy)
Plasma
comparison of plasma homovanillic acid concentrations in schizophrenic patients and normal controls [Davidson] 561 (Je)
double-blind comparison of alprazolam, diazepam, and placebo for treatment of negative schizophrenic symptoms [Csernansky] 655 (Jy)
neuroleptic plasma level may predict response in patients who meet criterion for improvement (letter) [Levinson] 878 (Se)
plasma monoamine metabolites in psychotic disorders [Bowers] 595 (Je)
Platelets see Blood Platelets
Pregnancy
adult schizophrenia following prenatal exposure to influenza epidemic [Mednick] 189 (Fe)
Premenstrual Syndrome
depressive symptoms and depressive diagnosis in community population, use of new procedure for analysis of psychiatric classification [Blazer] 1078 (De)
Prescriptions, Drug
prescribing of psychotropic medication by primary care physicians and psychiatrists [Beardsley] 1117 (De)
Primary Health Care
psychiatric disorders in pediatric primary care, prevalence and risk factors [Costello] 1107 (De)
Probability
estimates of prevalence of childhood maladjustment in community survey in Puerto Rico, use of combined measures [Bird] 1120 (De)
prevalence of specific psychiatric disorders among homeless individuals in inner city of Los Angeles [Koegel] 1085 (De)
Prognosis
hospital discharge status and long-term outcome for patients with schizophrenia, schizoaffective disorder, borderline personality disorder, and unipolar affective disorder [McGlashan] 363 (Ap)
neuroleptic plasma level may predict response in patients who meet criterion for improvement (letter) [Levinson] 878 (Se)
predicting hospital discharge status for patients with schizophrenia, schizoaffective disorder, borderline personality disorder, and unipolar affective disorder [Heinssen] 353 (Ap)
use of specialty psychiatric settings in constructing DRGs [Taube] 1037 (No)
Prolactin
carbon dioxide-induced anxiety, behavioral, physiologic, and biochemical effects of carbon dioxide in patients with panic disorders and healthy subjects [Woods] 43 (Ja)
methylphenidate and growth in hyperactive children, controlled withdrawal study [Klein] 1127 (De)
serotonergic responsivity in obsessive-compulsive disorder, effects of chronic clomipramine treatment [Zohar] 167 (Fe)
serotonin function in obsessive-compulsive disorder, comparison of effects of tryptophan and *m*-chlorophenylpiperazine in patients and healthy subjects [Charney] 177 (Fe)
simultaneous evaluation of multiple markers of ethanol/placebo challenges in sons of alcoholics and controls [Schuckit] 211 (Mr)
Prospective Payment System
simulating policy options for psychiatric care in general hospitals under Medicare's PPS [Freiman] 1032 (No)
toward a fairer prospective payment system [Essock] 1041 (No)
use of specialty psychiatric settings in constructing DRGs [Taube] 1037 (No)
Psychiatric Status Rating Scales
clozapine for treatment-resistant schizophrenic, double-blind comparison with chlorpromazine [Kane] 789 (Se)
composite international diagnostic interview, epidemiologic instrument suitable for use in conjunction with different diagnostic systems and in different cultures [Robins] 1069 (De)
depressive symptoms and depressive diagnosis in community population, use of new procedure for analysis of psychiatric classification [Blazer] 1078 (De)
efficacy study of iaocarboxazid and placebo in depression, and its relationship to depressive nosology [Davidson] 120 (Fe)
epidemiologic approaches to developmental psychopathology [Rutter] 486 (My)
inpatient family intervention, randomized clinical trial, II. results at hospital discharge [Haas] 217 (Mr)
prefrontal-type cognitive deficits and chronic psychiatric conditions (letter) [Wong] (reply) [Goldberg] 1054 (No)
prevalence of major depression, simple phobia, and other psychiatric disorders in patients with long-standing type I diabetes mellitus [Popkin] 64 (Ja)
siblings of disabled children, effects of chronic stress in family [Breslau] **44**:1040 (De); correction, **45**:196 (Fe)
structured interview guide for Hamilton depression rating scale [Williams] 742 (Au)
what is a case? food for thought for epidemiologists [Kendell] 374 (Ap)
what is a case? 45-year study of psychiatric impairment within college sample selected for mental health [Vaillant] 313 (Ap)
why are we rushing to publish *DSM-IV*? [Zimmerman] 1135 (De)
Psychiatry
prescribing of psychotropic medication by primary care physicians and psychiatrists [Beardsley] 1117 (De)
psychiatric disorders in pediatric primary care, prevalence and risk factors [Costello] 1107 (De)
what is a case? food for thought for epidemiologists [Kendell] 374 (Ap)
what is a case? 45-year study of psychiatric impairment within college sample selected for mental health [Vaillant] 313 (Ap)
Psychomotor Disorders
multiple-dose arecoline infusions in Alzheimer's disease [Tariot] 901 (Oc)
Psychopathology
early parental loss and development of psychopathology [Breier] 987 (No)
epidemiologic approaches to developmental psychopathology [Rutter] 486 (My)
outcome and familial psychopathology in schizophrenia [Kendler] 338 (Ap)
psychiatric disorders in pediatric primary care, prevalence and risk factors [Costello] 1107 (De)
siblings of disabled children, effects of chronic stress in family [Breslau] **44**:1040 (De); correction, **45**:196 (Fe)
Psychoses see Psychotic Disorders
Psychosis, Brief Reactive see Psychotic Disorders
Psychosis, Manic-Depressive see Bipolar Disorders
Psychotherapy
cause and treatment of agoraphobia (letter) [Lelliott] 388, (reply) [Klein] 389 (Ap)
clinicians can agree in assessing relationship patterns in psychotherapy, core conflictual relationship theme method [Crits-Christoph] 1001 (No)
Psychotic Disorders
causes of death in *DSM-III* schizophrenics and other psychotics (atypical group), comparison with general population [Buda] 283 (Mr)
controlled family study of chronic psychoses, schizophrenia and schizoaffective disorder [Gershon] 328 (Ap)
effect of ketoconazole on hypophysectomized, hypercortisolemic, psychotically depressed woman (letter) [Ravaris] 966 (Oc)
electroencephalographic sleep in mania [Hudson] 267 (Mr)
familial rates of affective disorder, report from National Institute of Mental Health Collaborative Study [Andreasen] **44**:461 (My); correction, **45**:776 (Au)
heritability of schizophrenia and schizoaffective disorder, family study [Coryell] 323 (Ap)
hospital discharge status and long-term outcome for patients with schizophrenia, schizoaffective disorder, borderline personality disorder, and unipolar affective disorder [McGlashan] 363 (Ap)
implications of normal brain development for pathogenesis of schizophrenia (letter) [Siris] 1055 (No)
plasma homovanillic acid as predictor of response to neuroleptics [Davila] 564 (Je)
plasma monoamine metabolites in psychotic disorders [Bowers] 595 (Je)
predicting hospital discharge status for patients with schizophrenia, schizoaffective disorder, borderline personality disorder, and unipolar affective disorder [Heinssen] 353 (Ap)
reliability of family history method for psychiatric diagnoses [Zimmerman] 320 (Ap)
selection of controls for family studies, biases and implications [Tsuang] 1006 (No)
single dominant gene can account for eye tracking dysfunctions and schizophrenia in offspring of discordant twins [Holzman] 641 (Jy)
Psychotropic Drugs
prescribing of psychotropic medication by primary care physicians and psychiatrists [Beardsley] 1117 (De)
PTSD see Stress Disorders, Posttraumatic
Public Health
depressive symptoms and depressive diagnosis in community population, use of new procedure for analysis of psychiatric classification [Blazer] 1078 (De)
prevalence of specific psychiatric disorders among homeless individuals in inner city of Los Angeles [Koegel] 1085 (De)
Publishing
meaning of full disclosure, collegial trust in science [Freedman] 689 (Jy)
request for retraction (letters) [Ferguson, Davidson, Poling] 685, 686, (editorial comment) [Freedman] 686 (Jy)
why are we rushing to publish *DSM-IV*? [Zimmerman] 1135 (De)
Puerto Rico
estimates of prevalence of childhood maladjustment in community survey in Puerto Rico, use of combined measures [Bird] 1120 (De)
Purkuit, Smooth see Eye Movements
Putamen
central D2-dopamine receptor occupancy in schizophrenic patients treated with antipsychotic drugs [Farde] 71 (Ja)

Q

Quality Control
'cause the Bible tells me so [Winokur] 683 (Jy)
Quality of Health Care
toward a fairer prospective payment system [Essock] 1041 (No)
Quality of Life
early parental loss and development of psychopathology [Breier] 987 (No)
Questionnaires
validity of self-report questionnaire for diagnosing major depressive disorder [Zimmerman] 738 (Au)

R

Rapid Eye Movements see Sleep, REM
Receptors, Adrenergic, Alpha
α_2-adrenergic receptor sensitivity in depression, plasma MHPG, behavioral, and cardiovascular responses to yohimbine [Heninger] 718 (Au)
Receptors, Adrenergic, Beta
lymphocyte β-adrenergic receptor modification in bulimia [Buckholtz] 479 (My)
Receptors, Dopamine
brain dopamine receptors in schizophrenia, PET problems (letter) [Seeman] 598, (reply) [Farde] 599 (Je)
central D2-dopamine receptor occupancy in schizophrenic patients treated with antipsychotic drugs [Farde] 71 (Ja)
physiological dysfunction of dorsolateral prefrontal cortex in schizophrenia, IV. further evidence for regional and behavioral specificity [Berman] 616 (Jy)
Rehabilitation
alcoholism among homeless adults in inner city of Los Angeles [Koegel] 1011 (No)
Reimbursement Mechanisms
prospective study of delirium and prolonged hospital stay, exploratory study [Thomas] 937 (Oc)
Research
autism and genetics, decade of research [Smalley] 953 (Oc)
brains of Vogt collection (letter) [Bogerts] 774 (Au)
civil commitment, relationship between perceived dan-

gerousness and mental illness [Mills] 770 (Au)
comment, on deaths of Ernst and Klaus H (letters) [Becker, Gershon] 774, 775 (Au)
differential effect of low and conventional doses of fluphenazine on schizophrenic outpatients with good or poor information-processing abilities [Asarnow] 822 (Se)
having a dream, research strategy for *DSM-IV* [Spitzer] 871 (Se)
meaning of full disclosure, collegial trust in science [Freedman] 689 (Jy)
prevalence of psychiatric disorders in primary care practice [Barrett] 1100 (De)
request for retraction (letters) [Ferguson, Davidson, Poling] 685, 686, (editorial comment) [Freedman] 686 (Jy)
why are we rushing to publish *DSM-IV*? [Zimmerman] 1135 (De)

Research Design
behavioral inhibition in children of parents with panic disorder and agoraphobia, controlled study [Rosenbaum] 463 (My)
cause and treatment of agoraphobia (letter) [Lelliott] 388, (reply) [Klein] 389 (Ap)
drug therapy for agoraphobia (letter) [Scott] (reply) [Klein] 387 (Ap)
familial rates of affective disorder, report from National Institute of Mental Health Collaborative Study [Andreasen] 44:461 (My); correction, 45:776 (Au)
selection of controls for family studies, biases and implications [Tsuang] 1006 (No)

Respiratory Muscles
hemodynamic, ventilatory, and biochemical responses of panic patients and normal controls with sodium lactate infusion and spontaneous panic attacks [Gaffney] 53 (Ja)

Retinoblastoma
association of autism, retinoblastoma, and reduced esterase D activity (letter) [Ritvo] 600 (Je)

Rhombencephalic Sleep see Sleep, REM

Risk Factors
clozapine for treatment-resistant schizophrenic, double-blind comparison with chlorpromazine [Kane] 789 (Se)
family genetic study of dementia of Alzheimer type [Martin] 594 (Oc)
husbands' layoff and wives' mental health, prospective analysis [Fenkower] 994 (No)
psychiatric disorders in pediatric primary care, prevalence and risk factors [Costello] 1107 (De)
risk factors for adolescent suicide, comparison of adolescent suicide victims with suicidal inpatients [Brent] 581 (Je)
single dominant gene can account for eye tracking dysfunctions and schizophrenia in offspring of discordant twins [Holzman] 641 (Jy)

Risk-Taking
pathological gambling, psychobiological study [Roy] 369 (Ap)
sensation seeking and behavior disorders (letter) [Zuckerman] 502, (reply) [Cloninger] 503 (My)

S

Saccades see Eye Movements

San Diego
San Diego Suicide Study, III. relationships between diagnoses and stressors [Rich] 589 (Je)

Schizoaffective Disorder see Psychotic Disorders

Schizophrenia
abnormal resting regional cerebral blood flow patterns and their correlates in schizophrenia [Mathew] 542 (Je)
adult schizophrenia following prenatal exposure to influenza epidemic [Mednick] 189 (Fe)
alprazolam augmentation of antipsychotic effects of fluphenazine in schizophrenic patients, preliminary results [Wolkowitz] 664 (Jy)
asymmetries in hemispheric control of attention in schizophrenia [Posner] 814 (Se)
brain dopamine receptors in schizophrenia, PET problems (letter) [Seeman] 596, (reply) [Farde] 599 (Je)
brains of Vogt collection (letter) [Bogerts] 774 (Au)
'cause the Bible tells me so [Winokur] 683 (Jy)
causes of death in *DSM-III* schizophrenics and other psychotics (atypical group), comparison with general population [Brad] 283 (Mr)
central D2-dopamine receptor occupancy in schizophrenic patients treated with antipsychotic drugs [Farde] 71 (Ja)
clozapine for treatment-resistant schizophrenic, double-blind comparison with chlorpromazine [Kane] 789 (Se)
comparison of plasma homovanillic acid concentrations in schizophrenic patients and normal controls [Davidson] 561 (Je)
computed tomographic evidence for generalized sulcal and ventricular enlargement in schizophrenia [Pfefferbaum] 633 (Jy)
controlled family study of chronic psychoses, schizophrenia and schizoaffective disorder [Gershon] 328 (Ap)
differential effect of low and conventional doses of fluphenazine on schizophrenic outpatients with good or poor information-processing abilities [Asarnow] 822 (Se)
dopamine metabolism and disposition in schizophrenic patients, studies using debrisoquin [Maas] 553 (Je)
dose of fluphenazine, familial expressed emotion, and outcome in schizophrenia, results of 2-year controlled study [Hogarty] 797 (Se)
double-blind comparison of alprazolam, diazepam, and placebo for treatment of negative schizophrenic symptoms [Csernansky] 655 (Jy)
effect of neuroleptics and tardive dyskinesia on smooth-pursuit eye movement in chronic schizophrenics [Spohn] 823 (Se)
effect of neuroleptics on altered cerebral glucose metabolism in schizophrenia [Szechtman] 523 (Je)
excess mortality among formerly hospitalized child psychiatric patients [Kuperman] 277 (Mr)
eye tracking dysfunction is associated with partial trisomy of chromosome 5 and schizophrenia (letter) [Iacono] 1140 (De)
familial aggregation of schizophrenia and schizophrenia spectrum disorders, evaluation of conflicting results [Kendler] 377 (Ap)
family factors and course of bipolar affective disorder [Miklowitz] 225 (Mr)
heritability of schizophrenia and schizoaffective disorder, family study [Coryell] 323 (Ap)
high correlations of norepinephrine, dopamine, and epinephrine and their major metabolite excretion rates [Linnoila] 701 (Au)
hospital discharge status and long-term outcome for patients with schizophrenia, schizoaffective disorder, borderline personality disorder, and unipolar affective disorder [McGlashan] 363 (Ap)
impairments on neuropsychologic tests of temporohippocampal and frontohippocampal functions and word fluency in remitting schizophrenia and affective disorders [Gruzelier] 623 (Jy)
implications of normal brain development for pathogenesis of schizophrenia (letter) [Siris] 1055 (No)
inpatient family intervention, randomized clinical trial, II. results at hospital discharge [Haas] 217 (Mr)
intracerebral inoculation of experimental animals with brain tissue from patients with schizophrenia, failure to observe consistent or specific behavioral and neuropathological effects [Kaufmann] 648 (Jy)
methylphenidate-induced information processing dysfunction in nonschizophrenic patients [Braff] 827 (Se)
neurodevelopmental model of schizophrenia (letters) [King, Lewine, Murray] 1051, 1052, (reply) [Weinberger] 1053 (No)
neuroleptic plasma level may predict response in patients who meet criterion for improvement (letter) [Levinson] 878 (Se)
outcome and familial psychopathology in schizophrenia [Kendler] 338 (Ap)
parental 'expressed emotion' as predictor of schizophrenic relapse [Parker] 806 (Se)
pharmacotherapy for patients with borderline personality disorder (letter) [Goldberg] 195, (reply) [Gunderson] 196 (Fe)
physiological dysfunction of dorsolateral prefrontal cortex in schizophrenia, III. new cohort and evidence for monoaminergic mechanism [Weinberger] 609; IV. further evidence for regional and behavioral specificity [Berman] 616 (Jy)
plasma homovanillic acid as predictor of response to neuroleptics [Davila] 564 (Je)
plasma 3-methoxy-4-hydroxyphenylglycol changes associated with clinical state and schizophrenic subtype [Ko] 842 (Se)
predicting hospital discharge status for patients with schizophrenia, schizoaffective disorder, borderline personality disorder, and unipolar affective disorder [Heinssen] 353 (Ap)
prefrontal-type cognitive deficits and chronic psychiatric conditions (letter) [Wong] (reply) [Goldberg] 1054 (No)
prevalence of specific psychiatric disorders among homeless individuals in inner city of Los Angeles [Koegel] 1085 (De)
psychiatric disability in female carriers of fragile X chromosome [Reiss] 25 (Ja)
quantitative neuroanatomy in schizophrenia, controlled magnetic resonance imaging study [Kelsoe] 533 (Je)
reliability of telephone interview in diagnosing anxiety disorders [Paulsen] 62 (Ja)
single dominant gene can account for eye tracking dysfunctions and schizophrenia in offspring of discordant twins [Holzman] 641 (Jy)
somatostatin immunoreactivity in postmortem brain from depressed suicides (letter) [Charlton] (reply) [Bissette] 597 (Je)
twin studies and genetic models of schizophrenia (letter) [Levinson] 876, (reply) [Farmer] 877 (Se)
validity of self-report questionnaire for diagnosing major depressive disorder [Zimmerman] 738 (Au)
who should receive clozapine? [Marder] 865 (Se)

Schizophreniform Disorders see Psychotic Disorders

Schizotypal Personality Disorder
familial aggregation of schizophrenia and schizophrenia spectrum disorders, evaluation of conflicting results [Kendler] 377 (Ap)

Science
meaning of full disclosure, collegial trust in science [Freedman] 689 (Jy)

Scopolamine Derivatives
effects of acute scopolamine in geriatric depression [Newhouse] 906 (Oc)

Seizures
excess mortality among formerly hospitalized child psychiatric patients [Kuperman] 277 (Mr)

Serotonin
serotonin function in obsessive-compulsive disorder, comparison of effects of tryptophan and *m*-chlorophenylpiperazine in patients and healthy subjects [Charney] 177 (Fe)

Serotonin Antagonists
serotonergic responsivity in obsessive-compulsive disorder, effects of chronic clomipramine treatment [Zohar] 167 (Fe)

Sex Behavior
sex chromosome anomalies, hormones, and sexuality [Schiavi] 19 (Ja)

Sex Chromosome Abnormalities
association of autism, retinoblastoma, and reduced esterase D activity (letter) [Ritvo] 600 (Je)
psychiatric disability in female carriers of fragile X chromosome [Reiss] 25 (Ja)
sex chromosome anomalies, hormones, and sexuality [Schiavi] 19 (Ja)

Sex Factors
autism and genetics, decade of research [Smalley] 953 (Oc)
one-month prevalence of mental disorders in United States, based on 5 epidemiologic catchment area sites [Regier] 977 (No)
prevalence of major depression, simple phobia, and other psychiatric disorders in patients with long-standing type I diabetes mellitus [Popkin] 64 (Ja)

Shock Therapy, Electric see Electroconvulsive Therapy

Sibling Relations
siblings of disabled children, effects of chronic stress in family [Breslau] 44:1040 (De); correction, 45:196 (Fe)

Sleep
cyclic delta peaks during sleep, result of pulsatile endocrine process? (letter) [Feinberg] 1140 (De)

Sleep Deprivation
electroencephalographic sleep in depressive pseudodementia [Buysse] 568 (Je)

Sleep, REM
cyclic delta peaks during sleep, result of pulsatile endocrine process? (letter) [Feinberg] 1140 (De)
electroencephalographic sleep in depressive pseudodementia [Buysse] 568 (Je)
electroencephalographic sleep in mania [Hudson] 267 (Mr)
electroencephalographic sleep profiles in recurrent depression, longitudinal investigation [Kupfer] 678 (Jy)
reliable discrimination of elderly depressed and demented patients by electroencephalographic sleep data [Reynolds] 258 (Mr)

Social Environment
husbands' layoff and wives' mental health, prospective analysis [Fenkower] 994 (No)

Social Support see Social Environment

Socialization
sensation seeking and behavior disorders (letter) [Zuckerman] 502, (reply) [Cloninger] 503 (My)

Socioeconomic Factors
husbands' layoff and wives' mental health, prospective analysis [Fenkower] 994 (No)
siblings of disabled children, effects of chronic stress in family [Breslau] 44:1040 (De); correction, 45:196 (Fe)

Sodium
hemodynamic, ventilatory, and biochemical responses of panic patients and normal controls with sodium lactate infusion and spontaneous panic attacks [Gaffney] 53 (Ja)

Somatization Disorder see Somatoform Disorders

Somatoform Disorders
one-month prevalence of mental disorders in United States, based on 5 epidemiologic catchment area sites [Regier] 977 (No)

Somatostatin
antisomatostatin IgG in major depressive disorder, preliminary study with implications for autoimmune mechanism of depression [Roy] 924 (Oc)
somatostatin immunoreactivity in postmortem brain from depressed suicides (letter) [Charlton] (reply) [Bissette] 597 (Je)

Somatostatin 14 see Somatostatin

Statistics
behavioral inhibition in children of parents with panic disorder and agoraphobia, controlled study [Rosenbaum] 463 (My)
estimates of prevalence of childhood maladjustment in community survey in Puerto Rico, use of combined measures [Bird] 1120 (De)
partial solution to base rate problem of κ statistic (letter) [Stewart] 504 (My)

Stress
metabolic stress produces rapid immunosuppression in humans (letter) [Breier] 44:1108 (De); correction 45:68 (Ja)

Stress Disorders, Posttraumatic
importance of past psychological trauma and pathophysiological process as determinants of current biologic abnormalities (letter) [Halbreich] 293 (Mr)

Stress, Psychological
parental loss in childhood, its effect in adult life [Tennant] 1045 (No)
siblings of disabled children, effects of chronic stress in family [Breslau] 44:1040 (De); correction, 45:196 (Fe)

Substance Abuse
complicated mania, comorbidity and immediate outcome in treatment of mania [Black] 232 (Mr)
controlled family study of chronic psychoses, schizophrenia and schizoaffective disorder [Gershon] 328 (Ap)
one-month prevalence of mental disorders in United States, based on 5 epidemiologic catchment area sites [Regier] 977 (No)
prevalence of psychiatric disorders among men infected with human immunodeficiency virus, controlled study [Atkinson] 859 (Se)
prevalence of psychiatric disorders in patients with alcohol and other drug problems [Ross] 1023 (No)
prevalence of specific psychiatric disorders among homeless individuals in inner city of Los Angeles [Koegel] 1085 (De)
reliability of family history method for psychiatric diagnoses [Zimmerman] 320 (Ap)
suicide and substance abuse [Murphy] 593 (Je)

Substance Withdrawal Syndrome
alprazolam in panic disorder and agoraphobia, results of multicenter trial, III. discontinuation effects [Pecknold] 429 (My)
long-term treatment of anxiety and risk of withdrawal, prospective comparison of clorazepate and buspirone [Rickels] 444 (My)
methylphenidate and growth in hyperactive children,

controlled withdrawal study [Klein] 1127 (De)
Suicide
causes of death in *DSM-III* schizophrenics and other psychotics (atypical group), comparison with general population [Buda] 283 (Mr)
reduced corticotropin releasing factor binding sites in frontal cortex of suicides [Nemeroff] 577 (Je)
risk factors for adolescent suicide, comparison of adolescent suicide victims with suicidal inpatients [Brent] 581 (Je)
San Diego Suicide Study, III. relationships between diagnoses and stressors [Rich] 589 (Je)
somatostatin immunoreactivity in postmortem brain from depressed suicides (letter) [Charlton] (reply) [Bissette] 597 (Je)
suicide and substance abuse [Murphy] 593 (Je)

T

Tacrine see Aminoacridine
Telephone
reliability of telephone interview in diagnosing anxiety disorders [Paulsen] 62 (Ja)
Temporal Lobe
impairments on neuropsychologic tests of temporohippocampal and frontohippocampal functions and word fluency in remitting schizophrenia and affective disorders [Gruzelier] 623 (Jy)
Termination, Employment see Unemployment
Tetracosactide see Cosyntropin
Tetracosactin see Cosyntropin
Tetrahydrocortisol see Hydrocortisone
Thiothixene
pharmacotherapy for patients with borderline personality disorder (letter) [Goldberg] 195, (reply) [Gunderson] 196 (Fe)
Thrombocytes see Blood Platelets
Tomography, Emission Computed
abnormal resting regional cerebral blood flow patterns and their correlates in schizophrenia [Mathew] 542 (Je)
brain dopamine receptors in schizophrenia, PET problems (letter) [Seeman] 598, (reply) [Farde] 599 (Je)
central D2-dopamine receptor occupancy in schizophrenic patients treated with antipsychotic drugs [Farde] 71 (Ja)
effect of neuroleptics on altered cerebral glucose metabolism in schizophrenia [Szechtman] 523 (Je)
Tomography, X-Ray Computed
alprazolam augmentation of antipsychotic effects of fluphenazine in schizophrenic patients, preliminary results [Wolkowitz] 664 (Jy)
comorbidity of borderline personality disorder [Fyer] 348 (Ap)
comparison of patients with and without poststroke major depression matched for size and location of lesion [Starkstein] 247 (Mr)
computed tomographic evidence for generalized sulcal and ventricular enlargement in schizophrenia [Pfefferbaum] 633 (Jy)
quantitative neuroanatomy in schizophrenia, controlled magnetic resonance imaging study [Kelsoe] 533 (Je)
Tranquilizing Agents, Major
central D2-dopamine receptor occupancy in schizophrenic patients treated with antipsychotic drugs [Farde] 71 (Ja)
clozapine for treatment-resistant schizophrenic, double-blind comparison with chlorpromazine [Kane] 789 (Se)
comparison of plasma homovanillic acid concentrations in schizophrenic patients and normal controls [Davidson] 561 (Je)
differential effect of low and conventional doses of fluphenazine on schizophrenic outpatients with good or poor information-processing abilities [Asarnow] 822 (Se)
dose of fluphenazine, familial expressed emotion, and outcome in schizophrenia, results of 2-year controlled study [Hogarty] 797 (Se)
double-blind comparison of alprazolam, diazepam, and placebo for treatment of negative schizophrenic symptoms [Csernansky] 655 (Jy)
effect of neuroleptics and tardive dyskinesia on smooth-pursuit eye movement in chronic schizophrenics [Spohn] 833 (Se)
effect of neuroleptics on altered cerebral glucose metabolism in schizophrenia [Szechtman] 523 (Je)
implications of normal brain development for pathogenesis of schizophrenia (letter) [Siris] 1055 (No)
neuroleptic plasma level may predict response in patients who meet criterion for improvement (letter) [Levinson] 878 (Se)
persistence of haloperidol in brain (letter) [Cohen] 879 (Se)
plasma homovanillic acid as predictor of response to neuroleptics [Davila] 564 (Je)
significance of neuroleptic dose and plasma level in pharmacological treatment of psychoses [Baldessarini] 79 (Ja)
who should receive clozapine? [Marder] 865 (Se)
Tranquilizing Agents, Minor
prescribing of psychotropic medication by primary care physicians and psychiatrists [Beardsley] 1117 (De)
Transplantation
prevalence of major depression, simple phobia, and other psychiatric disorders in patients with long-standing type I diabetes mellitus [Popkin] 64 (Ja)
Tranylcypromine
pharmacotherapy of borderline personality disorder, alprazolam, carbamazepine, trifluoperazine, and tranylcypromine [Cowdry] 111 (Fe)
Tricyclic Antidepressive Agents see Antidepressive Agents, Tricyclic
Trifluoperazine
pharmacotherapy of borderline personality disorder, alprazolam, carbamazepine, trifluoperazine, and tranylcypromine [Cowdry] 111 (Fe)
Trisomy
eye tracking dysfunction is associated with partial trisomy of chromosome 5 and schizophrenia (letter) [Iacono] 1140 (De)
Tropanes
clozapine for treatment-resistant schizophrenic, double-blind comparison with chlorpromazine [Kane] 739 (Se)
Tryptophan
serotonin function in obsessive-compulsive disorder, comparison of effects of tryptophan and *m*-chlorophenylpiperazine in patients and healthy subjects [Charney] 177 (Fe)
Twins
adoptee studies of psychiatric disorders (letter) [Donovan] (reply) [Kety] 875 (Se)
behavioral inhibition in children of parents with panic disorder and agoraphobia, controlled study [Rosenbaum] 463 (My)
brains of Vogt collection (letter) [Bogerts] 774 (Au)
single dominant gene can account for eye tracking dysfunctions and schizophrenia in offspring of discordant twins [Holzman] 641 (Jy)
twin studies and genetic models of schizophrenia (letter) [Levinson] 876, (reply) [Farmer] 877 (Se)
Twins, Dizygotic see Twins
Twins, Monozygotic see Twins
Tyramine
phenelzine vs placebo in 50 patients with bulimia [Walsh] 471 (My)

U

Unemployment
husbands' layoff and wives' mental health, prospective analysis [Penkower] 994 (No)
Unipolar Depression see Depressive Disorder
United States
one-month prevalence of mental disorders in United States, based on 5 epidemiologic catchment area sites [Regier] 977 (No)
United States Alcohol, Drug Abuse, and Mental Health Administration
composite international diagnostic interview, epidemiologic instrument suitable for use in conjunction with different diagnostic systems and in different cultures [Robins] 1069 (De)
request for retraction (letters) [Ferguson, Davidson, Poling] 685, 686, (editorial comment) [Freedman] 686 (Jy)
United States Food and Drug Administration
where are those new antidepressants we were promised? [Cole] 193 (Fe)
United States Health Services and Mental Health Administration see United States Alcohol, Drug Abuse and Mental Health Administration
Urination
high intercorrelations among urinary outputs of norepinephrine and its major metabolites, replication in depressed patients and controls [Roy] 158 (Fe)
Urine
cerebrospinal fluid and urinary biogenic amines in depressed patients and healthy controls [Davis] 705 (Au)
high correlations of norepinephrine, dopamine, and epinephrine and their major metabolite excretion rates [Linnoila] 701 (Au)
norepinephrine and its metabolites in cerebrospinal fluid, plasma, and urine, relationship to hypothalamic-pituitary-adrenal axis function in depression [Roy] 849 (Se)
pathological gambling, psychobiological study [Roy] 369 (Ap)

V

Ventilatory Muscles see Respiratory Muscles
Violence
civil commitment in psychiatric emergency room, I. assessment of dangerousness by emergency room clinicians [Segal] 748; II. mental disorder indicators and 3 dangerousness criteria [Segal] 753; III. disposition as function of mental disorder and dangerousness indicators [Segal] 759 (Au)
civil commitment, relationship between perceived dangerousness and mental illness [Mills] 770 (Au)
limitations on psychiatrists' discretionary civil commitment authority by Stone and dangerousness criteria [Hoge] 764 (Au)
Visual Fields
asymmetries in hemispheric control of attention in schizophrenia [Posner] 814 (Se)

W

Withdrawal Symptoms see Substance Withdrawal Syndrome
World Health Organization
composite international diagnostic interview, epidemiologic instrument suitable for use in conjunction with different diagnostic systems and in different cultures [Robins] 1069 (De)

X

X Chromosome
autism and genetics, decade of research [Smalley] 953 (Oc)
Xenon
abnormal resting regional cerebral blood flow patterns and their correlates in schizophrenia [Mathew] 542 (Je)
physiological dysfunction of dorsolateral prefrontal cortex in schizophrenia, III. new cohort and evidence for monoaminergic mechanism [Weinberger] 609 (Jy)
XYY Karyotype see Sex Chromosome Abnormalities

Y

Yohimbine
α_2-adrenergic receptor sensitivity in depression, plasma MHPG, behavioral, and cardiovascular responses to yohimbine [Heninger] 718 (Au)

Z

Zimeldine
where are those new antidepressants we were promised? [Cole] 193 (Fe)